Embecta (EMBC) 10-K 11 Dec 24 2024 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Nov. 29, 2024	Mar. 31, 2024
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Sep. 30, 2024
Current Fiscal Year End Date	--09-30
Document Transition Report	false
Entity File Number	001-41186
Entity Registrant Name	EMBECTA CORP.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-1583942
Entity Address, Address Line One	300 Kimball Drive, Suite 300
Entity Address, City or Town	Parsippany
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07054
City Area Code	862
Local Phone Number	401-0000
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	EMBC
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction Flag	false
Entity Shell Company	false
Entity Public Float			$ 763
Entity Common Stock, Shares Outstanding		58,130,561
Documents Incorporated by Reference	The information required by Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K is incorporated by reference to the Registrant’s definitive proxy statement for its 2025 Annual Meeting of Stockholders (the “2025 Proxy Statement”), which will be filed pursuant to Regulation 14A with the United States Securities and Exchange Commission (“SEC”) within 120 days after the end of the fiscal year to which this report relates.
Central Index Key	0001872789
Period Focus	FY
Fiscal Year Focus	2024
Amendment Flag	false

Audit Information

Audit Information	12 Months Ended
	Sep. 30, 2024
Audit Information [Abstract]
Auditor Name	ERNST & YOUNG LLP
Auditor Location	New York, New York
Auditor Firm ID	42

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Millions		12 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenues		$ 1,123.1	$ 1,120.8	$ 1,129.5
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]		Product [Member]	Product [Member]	Product [Member]
Cost of products sold	[1]	$ 387.9	$ 370.9	$ 354.6
Cost, Product and Service [Extensible Enumeration]		Product [Member]	Product [Member]	Product [Member]
Gross Profit		$ 735.2	$ 749.9	$ 774.9
Operating expenses:
Selling and administrative expense		365.1	341.3	294.8
Research and development expense		78.8	85.2	66.9
Impairment expense		0	2.5	58.9
Other operating expenses		124.5	99.4	44.7
Total Operating Expenses		568.4	528.4	465.3
Operating Income		166.8	221.5	309.6
Interest expense, net		(112.3)	(107)	(46.2)
Other income (expense), net		(10.3)	(8.8)	(6.8)
Income Before Income Taxes		44.2	105.7	256.6
Income tax provision (benefit)		(34.1)	35.3	33
Net Income		$ 78.3	$ 70.4	$ 223.6
Net Income per common share:
Basic (in dollars per share)		$ 1.36	$ 1.23	$ 3.92
Diluted (in dollars per share)		$ 1.34	$ 1.22	$ 3.89
[1] For the period prior to the Separation, this income statement line includes cost of products sold from related party inventory purchases. Refer to Note 4 for further detail.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net Income	$ 78.3	$ 70.4	$ 223.6
Other Comprehensive Income (Loss), net of tax
Benefit plan net loss and prior service credit, net of amortization	(1.7)	(1.6)	0
Foreign currency translation adjustments	18	17.4	(64.2)
Total Other Comprehensive Income (Loss), net of tax	16.3	15.8	(64.2)
Comprehensive Income	$ 94.6	$ 86.2	$ 159.4

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Current Assets
Cash and equivalents	$ 267.5	$ 326.3
Restricted cash	6.7	0.2
Trade receivables, net (net of allowance for doubtful accounts of $2.8 million and $1.0 million as of September 30, 2024 and September 30, 2023, respectively)	193	16.7
Inventories:
Materials	40.4	32.1
Work in process	4.8	8.1
Finished products	126.3	111.9
Total Inventories	171.5	152.1
Amounts due from Becton, Dickinson and Company	53.8	142.4
Prepaid expenses and other	68.5	111.4
Total Current Assets	761	749.1
Property, Plant and Equipment, Net	290.4	300.2
Goodwill and Intangible Assets	23.7	24.7
Deferred Income Taxes and Other Assets	210.2	140.4
Total Assets	1,285.3	1,214.4
Current Liabilities
Accounts payable	91	53.5
Accrued expenses	134.2	118.1
Amounts due to Becton, Dickinson and Company	42.5	73.1
Salaries, wages and related items	66.7	62.1
Current debt obligations	9.5	9.5
Current finance lease liabilities	3.4	3.6
Income taxes	26.7	33.6
Total Current Liabilities	374	353.5
Deferred Income Taxes and Other Liabilities	54.1	57.2
Long-Term Debt	1,565.3	1,593.9
Non Current Finance Lease Liabilities	30.2	31.5
Contingencies (Note 7)
Embecta Corp. Equity
Common stock, $0.01 par value Authorized - 250,000,000 Issued and outstanding - 57,707,285 as of September 30, 2024 and 57,333,353 as of September 30, 2023	0.6	0.6
Additional paid-in capital	52.5	27.9
Accumulated deficit	(498.6)	(541.1)
Accumulated other comprehensive loss	(292.8)	(309.1)
Total Equity	(738.3)	(821.7)
Total Liabilities and Equity	$ 1,285.3	$ 1,214.4

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Statement of Financial Position [Abstract]
Trade receivables, allowance for doubtful accounts	$ 2.8	$ 1
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	250,000,000	250,000,000
Common stock, issued (in shares)	57,707,285	57,333,353
Common stock, outstanding (in shares)	57,707,285	57,333,353

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Net Investment from Becton, Dickinson and Company	Accumulated Other Comprehensive (Loss) Income
Beginning balance (in shares) at Sep. 30, 2021		0
Beginning balance at Sep. 30, 2021	$ 594.3	$ 0	$ 0	$ 0	$ 864.8	$ (270.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net transfers to Becton, Dickinson and Company including Separation adjustments	(380.5)				(390.3)	9.8
Issuance of common stock in connection with the Separation and reclassification of Net Investment from Becton, Dickinson and Company (in shares)		57,012,925
Issuance of common stock in connection with the Separation and reclassification of Net Investment from Becton, Dickinson and Company	0	$ 0.6		(613.7)	613.1
Net consideration paid to Becton, Dickinson, and Company in connection with Separation	(1,266)				(1,266)
Net income attributable to Embecta Corp.	223.6			45.2	178.4
Other comprehensive income (loss), net of taxes	(64.2)					(64.2)
Stock-based compensation plans	10		10
Dividends and dividend equivalents declared	(8.6)			(8.6)
Issuance of shares related to share-based compensation plans (in shares)		42,402
Ending balance (in shares) at Sep. 30, 2022		57,055,327
Ending balance at Sep. 30, 2022	(891.4)	$ 0.6	10	(577.1)	0	(324.9)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Embecta Corp.	70.4			70.4
Other comprehensive income (loss), net of taxes	15.8					15.8
Stock-based compensation plans	21.5		21.5
Dividends and dividend equivalents declared	(34.4)			(34.4)
Issuance of shares related to share-based compensation plans (in shares)		278,026
Issuance of shares related to stock-based compensation plans	$ (3.6)		(3.6)
Ending balance (in shares) at Sep. 30, 2023	57,333,353	57,333,353
Ending balance at Sep. 30, 2023	$ (821.7)	$ 0.6	27.9	(541.1)	0	(309.1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Embecta Corp.	78.3			78.3
Other comprehensive income (loss), net of taxes	16.3					16.3
Stock-based compensation plans	26.3		26.3
Dividends and dividend equivalents declared	(34.5)		1.3	(35.8)
Issuance of shares related to share-based compensation plans (in shares)		373,932
Issuance of shares related to stock-based compensation plans	$ (3)		(3)
Ending balance (in shares) at Sep. 30, 2024	57,707,285	57,707,285
Ending balance at Sep. 30, 2024	$ (738.3)	$ 0.6	$ 52.5	$ (498.6)	$ 0	$ (292.8)

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical) - $ / shares	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Statement of Stockholders' Equity [Abstract]
Dividend declared (in dollars per share)	$ 0.60	$ 0.60	$ 0.15

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Operating Activities
Net Income	$ 78,300,000	$ 70,400,000	$ 223,600,000
Adjustments to net income to derive net cash provided by operating activities:
Depreciation and amortization	36,200,000	32,600,000	31,700,000
Amortization of debt issuance costs	6,900,000	6,400,000	3,200,000
Amortization of cloud computing costs	6,300,000	0	0
Impairment of property, plant and equipment	0	2,500,000	58,900,000
Stock-based compensation	26,300,000	21,500,000	18,700,000
Deferred income taxes	(70,600,000)	14,300,000	(26,500,000)
Change in operating assets and liabilities:
Trade receivables, net	(174,700,000)	7,000,000	122,700,000
Inventories	(16,500,000)	(28,800,000)	(23,400,000)
Due from/due to Becton, Dickinson and Company	58,900,000	(23,200,000)	(47,000,000)
Prepaid expenses and other	39,500,000	(14,200,000)	(44,000,000)
Accounts payable, accrued expenses and other current liabilities	60,000,000	7,900,000	76,900,000
Income and other net taxes payable	13,200,000	(12,600,000)	10,300,000
Other assets and liabilities, net	(28,100,000)	(16,100,000)	7,100,000
Net Cash Provided by Operating Activities	35,700,000	67,700,000	412,200,000
Investing Activities
Capital expenditures	(15,800,000)	(26,500,000)	(23,600,000)
Acquisition of intangible assets	0	0	(400,000)
Net Cash Used for Investing Activities	(15,800,000)	(26,500,000)	(24,000,000)
Financing Activities
Proceeds from the issuance of long-term debt	0	0	1,450,000,000
Payments on long-term debt	(34,600,000)	(9,500,000)	(4,800,000)
Payment of long-term debt issuance costs	0	0	(33,300,000)
Payment of revolving credit facility fees	0	0	(5,600,000)
Payments related to tax withholding for stock-based compensation	(3,000,000)	(3,600,000)	0
Payments on finance lease	(1,300,000)	(1,200,000)	(1,800,000)
Dividend payments	(34,500,000)	(34,400,000)	(8,600,000)
Net consideration paid to Becton, Dickinson and Company in connection with the Separation	0	0	(1,266,000,000)
Net transfers to Becton, Dickinson and Company	0	0	(177,900,000)
Net Cash Used for Financing Activities	(73,400,000)	(48,700,000)	(48,000,000)
Effect of exchange rate changes on cash and equivalents and restricted cash	1,200,000	3,100,000	(9,300,000)
Net Change in Cash and equivalents and restricted cash	(52,300,000)	(4,400,000)	330,900,000
Opening Cash and equivalents and restricted cash	326,500,000	330,900,000	0
Closing Cash and equivalents and restricted cash	$ 274,200,000	$ 326,500,000	$ 330,900,000

Background

Background	12 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background	Note 1 — Background Embecta Corp. ("Embecta" or the "Company") is a leading global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. The Company has a broad portfolio of marketed products, including a variety of pen needles, syringes and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The Company primarily sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. On April 1, 2022 (the "Separation Date"), Embecta and Becton, Dickinson and Company ("BD") entered into a Separation and Distribution Agreement (the "Separation and Distribution Agreement"). Pursuant to the Separation and Distribution Agreement, BD agreed to spin off its diabetes care business (the "Diabetes Care Business") into Embecta, a new, publicly traded company (the "Separation"). The Separation occurred by means of a pro-rata distribution (the "Distribution") of all of Embecta’s issued and outstanding shares of common stock on the basis of one share of Embecta common stock, par value $0.01 per share, for every five shares of BD common stock, par value $1.00 per share, held as of the close of business on March 22, 2022, the record date for the distribution. Embecta is now a standalone publicly traded company and, on April 1, 2022, regular-way trading of Embecta common stock commenced on the Nasdaq Global Select Market under the ticker symbol "EMBC". In connection with the Separation, BD and Embecta entered into various agreements to provide a framework for the relationship between BD and Embecta after the Separation, including, but not limited to, a separation and distribution agreement, a transition services agreement, a tax matters agreement, an employee matters agreement, a cannula supply agreement, contract manufacturing agreements, an intellectual property matters agreement, a logistics services agreement, distribution agreements, factoring and receivables agreements, local support and service agreements and other transaction documents. As of October 31, 2024, all of the factoring and trade receivables agreements and the distribution agreements and local support and services agreements have expired and terminated.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Note 2 — Basis of Presentation On April 1, 2022, the Company became a standalone publicly traded company, and its financial statements are now presented on a consolidated basis. Prior to the Separation on April 1, 2022, the Company’s historical combined financial statements were prepared on a standalone basis and were derived from BD's consolidated financial statements and accounting records. The financial statements for all periods presented, including the historical results of the Company prior to April 1, 2022, are now referred to as "Consolidated Financial Statements", and have been prepared pursuant to the rules and regulations for reporting on Form 10-K. Periods Prior to Separation Prior to the Separation, the Company was referred to as the Diabetes Care Business. The assets, liabilities, revenue and expenses of the Diabetes Care Business were reflected in the combined financial statements on a historical cost basis, as included in the consolidated financial statements of BD, using the historical accounting policies applied by BD. The Consolidated Financial Statements did not purport to reflect what the Company’s results of operations, comprehensive income, financial position, equity or cash flows would have been had the Company operated as a standalone public company during the periods presented. The Diabetes Care Business had historically functioned together with the other businesses controlled by BD. Accordingly, the Diabetes Care Business relied on BD’s corporate and other support functions for its business. Therefore, for the period prior to the Separation, certain corporate and shared costs were allocated to the Diabetes Care Business based on a specific identification basis or, when specific identification was not practicable, a proportional cost allocation method, including: i. expenses related to BD support functions, including expenses for facilities, executive oversight, treasury, finance, legal, human resources, shared services, compliance, procurement, information technology and other corporate functions. ii. certain manufacturing and supply costs incurred by BD, including facility management, distribution, logistics, planning and global quality. iii. certain costs incurred by BD’s Medication Delivery Solutions organizational unit in relation to selling and marketing activities, and related administrative support functions. iv. certain costs incurred by BD for activities related to device research and development, as well as medical and regulatory affairs. v. stock-based compensation expenses (see Note 10). vi. certain compensation expenses maintained on a centralized basis such as certain employee benefit expenses. Management believes these cost allocations were a reasonable reflection of the utilization of services provided to, or the benefit derived by, the Diabetes Care Business during the period prior to the Separation, though the allocations may not be indicative of the actual costs that would have been incurred had the Diabetes Care Business operated as a standalone public company. Actual costs that may have been incurred if the Diabetes Care Business had been a standalone company would depend on a number of factors, including the chosen organizational structure, whether functions were outsourced or performed by Diabetes Care Business employees, and strategic decisions made in areas such as manufacturing, selling and marketing, research and development, information technology and infrastructure. BD utilized a centralized approach to cash management and the financing of its operations. Cash generated by the Diabetes Care Business was routinely transferred into accounts managed by BD’s centralized treasury function and cash disbursements related to operations prior to the Separation were funded as needed by BD. Balances held by the Diabetes Care Business with BD for cash transfers and loans were reflected as Amounts due to Becton, Dickinson and Company prior to the Separation. All other cash and equivalents and related transfers between BD and the Diabetes Care Business were generally held centrally through accounts controlled and maintained by BD and were not specifically identifiable to the Diabetes Care Business. Accordingly, such balances were accounted for through Net Investment from Becton, Dickinson and Company . BD’s third-party debt and related interest expense were not attributed to the Diabetes Care Business because the business was not the legal obligor of the debt and the borrowings were not specifically identifiable to the business. For the Diabetes Care Business, transactions with BD affiliates were included in the Consolidated Statements of Income and related balances were reflected as Amounts due to Becton, Dickinson and Company or Amounts due from Becton, Dickinson and Company . Other balances between the Diabetes Care Business and BD were considered to be effectively settled in the Consolidated Financial Statements at the time the transactions were recorded. As the separate legal entities that made up the Diabetes Care Business were not historically held by a single legal entity, Net Investment from Becton, Dickinson and Company was shown in lieu of stockholders’ equity in these Consolidated Financial Statements. Net Investment from Becton, Dickinson and Company represented BD’s interest in the recorded assets of the Diabetes Care Business and the cumulative investment by BD through the date of the Separation, inclusive of operating results. For periods prior to the Separation, income tax expense and tax balances in the Consolidated Financial Statements were calculated on a separate tax return basis. The separate tax return method applies the accounting guidance for income taxes to the standalone financial statements as if the Company was a separate taxpayer and a standalone enterprise. Management believes the assumptions supporting the allocation and presentation of income taxes on a separate return basis are reasonable. The provision for income taxes for the period prior to the Separation was calculated by applying an estimated effective income tax rate for the full year to ordinary income adjusted by the tax impact of discrete items. As of the Separation Date Certain assets and liabilities, including patents and unrecognized tax benefits that were included in the Consolidated Balance Sheet prior to the Separation, have been retained by BD post-Separation and therefore were transferred to BD through Net Investment from Becton, Dickinson and Company in the Company's Consolidated Financial Statements. In connection with the Separation, additional pension assets, deferred tax assets, other compensation obligations, and certain other assets and liabilities were transferred to the Company through Net Investment from Becton, Dickinson and Company , and the Company recorded these in the Consolidated Balance Sheet. As part of the Separation, Net Investment from Becton, Dickinson and Company was reclassified as Common Stock and Accumulated Deficit . Periods Post Separation Following the Separation, certain functions continue to be provided by BD under the Transition Services Agreements or are being performed using Embecta’s own resources or third-party service providers. Additionally, under manufacturing and supply agreements, the Company manufactures certain products for BD, or its applicable affiliate and BD manufactures certain products for the Company. The Company incurred certain costs in its establishment as a standalone public company and expects to incur ongoing additional costs associated with operating as an independent, publicly traded company. All intercompany transactions and accounts within Embecta have been eliminated.

Summary of Accounting Policies

Summary of Accounting Policies	12 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Accounting Policies	Note 3 — Summary of Accounting Policies Revenue Recognition The Company recognizes revenue from product sales and considers performance obligations satisfied when the customer obtains control of the product, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. The Company acts as the principal in its customer arrangements and therefore records revenue on a gross basis. When arrangements include multiple performance obligations, the total transaction price of the contract is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. The point in time upon which shipment or delivery occurs is the most faithful depiction of when control of the goods transfers to the customer. Variable consideration such as rebates, chargebacks, sales discounts, and sales returns are estimated and treated as a reduction of revenue in the same period the related revenue is recognized. These estimates are based on contractual terms, historical practices and current trends, and are adjusted as new information becomes available. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. Additional disclosures regarding the Company’s accounting for revenue recognition are provided in Note 8. Cash and Equivalents Cash and equivalents include all highly liquid investments with a maturity of three months or less at the date of acquisition. Interest income on Cash and equivalents is recorded as earned. Restricted Cash Restricted cash consists of cash not readily available for use in the Company's operating activities and is primarily pledged as collateral for bank guarantees related to certain customer performance guarantees and property leases internationally, which are further discussed in Note 16. Trade Receivables The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The allowance for doubtful accounts represents the Company’s estimate of probable credit losses relating to trade receivables and is determined based on historical experience, current conditions, reasonable and supportable forecasts and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. Inventories Inventories are stated at the lower of approximate cost or net realizable value determined on the first-in, first-out basis. Cloud Computing Arrangements The Company capitalizes costs incurred to implement cloud computing arrangements that are service contracts within Prepaid expenses and other and Deferred Income Taxes and Other Assets in the Company's Consolidated Balance Sheets based on the expected period that amortization will be recognized. Implementation costs associated with cloud computing arrangements are capitalized when incurred during the application development phase. Once the implementation of a cloud computing arrangement is complete and ready for its intended use, the Company amortizes the costs over the expected term of the hosting arrangement using the straight-line method to the same income statement line as the associated cloud operating expenses. Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is principally provided on the straight-line basis over estimated useful lives, which range from 20 to 45 years for buildings, 4 to 13 years for machinery and equipment and 1 to 20 years for leasehold improvements. Depreciation expense was $34.9 million in 2024, $31.5 million in 2023, and $31.0 million in 2022. Property, plant and equipment are periodically reviewed when impairment indicators are present to assess recoverability or a decision has been made to abandon efforts associated with construction in progress assets. Recoverability is determined by comparing the carrying values of the assets or asset groups to the undiscounted cash flows to be generated from the use and eventual disposition of such assets or asset groups. If the asset’s or asset group’s carrying value exceeds such undiscounted cash flows, the assets or asset groups are not recoverable and an impairment loss is recognized based on the amount by which the carrying value of the asset or asset group exceeds its calculated fair value. Capitalized Interest The interest cost on capital projects is capitalized and included in the cost of the project. Capitalization commences with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use. When no debt is incurred specifically for a project, interest is capitalized on project expenditures using the weighted average cost of the Company's outstanding borrowings. For the fiscal years ended September 30, 2024, 2023 and 2022 the Company capitalized $3.7 million, $4.6 million and $5.2 million of interest expense, respectively, into Property, Plant and Equipment, Net . For the fiscal year ended September 30, 2023 the Company capitalized $0.9 million of interest expense into Deferred Income Taxes and Other Assets. Interest expense capitalized into Deferred Income Taxes and Other Assets during the fiscal year ended September 30, 2024 is not material to the Company’s Consolidated Financial Statements. Advertising Costs Advertising costs are expensed as incurred and included in S elling and administrative expense . The Company recorded advertising costs of $9.0 million, $15.5 million, and $11.6 million in 2024, 2023, and 2022, respectively. Goodwill and Other Intangible Assets Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. The Company has one reporting unit. Goodwill is evaluated for impairment as of July 1 each year, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that fair value is less than carrying value. If the Company concludes it is more likely than not that fair value is less than carrying value, a quantitative fair value test is performed. If carrying value is greater than fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill). The Company completed the annual goodwill impairment test as of July 1, 2024 and concluded that no impairment to goodwill was necessary as the fair value of the Company's one reporting unit was significantly in excess of the carrying value. No goodwill impairments were identified during the fiscal years ended September 30, 2024, 2023, or 2022, and no accumulated impairment losses are recorded. Amortized intangible assets primarily consist of patents and customer relationships. Patents are generally amortized over 20 years using the straight-line method. Customer relationship assets are generally amortized over periods ranging from 10 to 15 years, using the straight-line method. Other intangibles with finite useful lives are amortized over periods principally ranging from 1 to 40 years, using the straight-line method. Finite-lived intangible assets are periodically reviewed when impairment indicators are present to assess recoverability from future operations using undiscounted cash flows. The carrying values of these finite-lived assets are compared to the undiscounted cash flows they are expected to generate and an impairment loss is recognized in operating results to the extent any finite-lived intangible asset’s carrying value exceeds its calculated fair value. Foreign Currency and Derivative Financial Instruments Assets and liabilities denominated in their functional currencies are translated into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates of exchange prevailing during the period. The United States dollar results that arise from such translation are included in Accumulated other comprehensive loss . The Company utilizes derivative instruments to manage market risks associated with fluctuations in certain foreign currency exchange rates. The Company utilizes foreign currency forward contracts to protect against market risks arising in the normal course of business. At the end of the reporting period, foreign-currency-denominated assets and liabilities are remeasured into the functional currencies of the reporting entities at current market rates. The change in value from this remeasurement is reported as a foreign exchange gain or loss for that period in Other income (expense), net . The Company recorded transactional foreign exchange losses of $4.4 million during the fiscal year ended September 30, 2024. For the fiscal years ended September 30, 2023 and 2022, transactional foreign exchange impacts were not material to the Company's Consolidated Statements of Income. Shipping and Handling Costs The Company considers its shipping and handling costs to be contract fulfillment costs and records them within selling and administrative expense. Shipping and handling costs were $41.3 million, $36.9 million, and $27.4 million in 2024, 2023, and 2022, respectively. Contingencies The Company establishes accruals for future losses which are both probable and can be reasonably estimated (and in the case of environmental matters, without considering possible third-party recoveries). Additional disclosures regarding the Company’s accounting for contingencies are provided in Note 7. Stock-Based Compensation Prior to the Separation, certain of the Company’s employees historically participated in BD’s stock-based compensation plans. Stock-based compensation expense was either allocated to the Company based on a proportionate cost allocation method or recorded based on specific identification. Effective April 1, 2022, the Company established the 2022 Employee and Director Equity Based Compensation Plan, as amended on February 7, 2024 (the "Plan"). The Plan provides for the grant of various types of awards, including restricted stock unit ("RSU") awards, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and generally may not be less than the fair market value per share on that date. The Company measures stock-based compensation for equity awards at fair value on the date of grant and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards. For awards that ultimately settle in cash, we treat them as liability awards and mark the award to market each reporting period and recognize any adjustment in our Consolidated Statements of Income. The Company recognizes stock-based compensation cost only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants. The cumulative effect on current and prior periods of a change in the estimated forfeiture rate is recognized as compensation cost in earnings in the period of the change (see Note 10). Benefit Plans Prior to the Separation, the defined benefit plans in which the Company participated related primarily to plans sponsored by BD and for which other businesses of BD also participate (the "Shared Plans"). The Company accounted for the Shared Plans as multiemployer plans and therefore the related assets and liabilities were not reflected in the Consolidated Balance Sheets. For such periods prior to the Separation, the Consolidated Statements of Income reflect a proportional allocation of net periodic benefit cost for the Shared Plans associated with the Company. The Company's participation in the defined pension and postretirement benefit plans sponsored by BD concluded upon the completion of the Separation on April 1, 2022. At and after Separation, Embecta became the plan sponsor for certain non-United States defined benefit pension plans (see Note 19). Research and Development Research and development costs are expensed as incurred. Income Taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax basis of assets and liabilities at the applicable tax rates. The Company maintains valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances are included in the tax provision in the period of change. In determining whether a valuation allowance is warranted, the Company evaluates factors such as prior earnings history, expected future earnings, carryback and carryforward periods, and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. From time to time, the Company engages in transactions in which tax consequences may be subject to uncertainty. The Company conducts business and files tax returns in numerous jurisdictions based on its interpretation of tax laws and regulations. In evaluating the Company’s tax provision, the Company establishes a reserve for uncertain tax positions unless such positions are determined to be more likely than not of being sustained upon examination based on the technical merits. The Company’s policy is to recognize, when applicable, interest and penalties on uncertain tax positions as part of income tax expense. While the Company believes it has identified all reasonable exposures and the reserve it has established is appropriate under the circumstances, it is possible that additional exposures exist and that exposures may be settled at amounts different than the amounts reserved. It is also possible that changes in facts and circumstances could cause the Company to either materially increase or reduce the carrying amount of its tax reserve. The Tax Cuts and Jobs Act was enacted on December 22, 2017 and introduced an additional United States tax on the earnings of non-United States subsidiaries which are referred to as Global Intangible Low Taxed Income (“GILTI”). The Company has elected to treat GILTI as a period cost. Prior to the Separation, the Company's operations were included in the tax returns of BD. Income taxes as presented in the Consolidated Financial Statements attribute current and deferred income tax assets and liabilities of BD to the Company in a manner that is systematic, rational, and consistent with the asset and liability method prescribed by the accounting guidance for income taxes. The Company's income tax provision prior to the Separation was prepared using the separate return method. The separate return method applies the accounting guidance for income taxes to the standalone financial statements as if the Company were a separate taxpayer and a standalone enterprise. The Company believes the assumptions supporting the allocation and presentation of income taxes on a separate return basis are reasonable. Additional disclosures regarding the Company's accounting for income taxes are provided in Note 15. Segment Data The Company operates and reports its financial information as one segment. In making this determination, the Company (i) determines its Chief Operating Decision Maker (“CODM”), (ii) identifies and analyzes potential business components, (iii) identifies its operating segments and (iv) determines whether there are multiple operating segments requiring presentation as reportable segments. The Company’s decision to report as one segment is based upon the following: (1) its internal organizational structure; (2) the manner in which its operations are managed; and (3) the criteria used by the Company’s President, its CODM, to evaluate performance of the Company’s business and allocate resources and capital. Fair Value Measurements A fair value hierarchy is applied to prioritize inputs used in measuring fair value. The three levels of inputs used to measure fair value are detailed below. Additional disclosures regarding the Company’s fair value measurements are provided in Note 16. Level 1—Inputs to the valuation methodology which represent unadjusted quoted prices in active markets for identical assets and liabilities. Level 2—Inputs to the valuation methodology which include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3—Inputs to the valuation methodology which are unobservable and significant to the fair value measurement. Leases The Company determines whether an arrangement contains a lease at inception. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability in the Company's Consolidated Balance Sheets and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12 months. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to Embecta by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that the Company is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases. Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the implicit rate is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease. For lease arrangements that are recognized on the Company’s Consolidated Balance Sheets, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain the Company will exercise the option. Finance leases are recorded in Property, Plant and Equipment, Net , Current finance lease liabilities , and Non Current Finance Lease Liabilities and operating leases are recorded in Deferred Income Taxes and Other Assets , Accrued expenses , and Deferred Income Taxes and Other Liabilities in the Company's Consolidated Balance Sheets. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates or assumptions affect reported assets, liabilities, revenues and expenses, including determining the allocation of shared costs and expenses from BD for the period prior to the Separation, depreciable and amortizable lives, sales returns and allowances, rebate accruals, restructuring costs, inventory reserves and taxes on income as reflected in the Consolidated Financial Statements. Actual results could differ from these estimates. Supplemental Disclosures Of Cash Flow Information Cash paid for interest related to debt during the fiscal year ended September 30, 2024, 2023 and 2022 was $117.7 million, $111.0 million and $38.9 million, respectively. Cash paid for income taxes, net of refunds, for the fiscal years ended September 30, 2024, 2023 and 2022 was $29.1 million, $30.4 million and $15.6 million, respectively. Recently Issued Accounting Standards Not Yet Adopted In November 2023, the Financial Accounting Standards Board issued Accounting Standards Update ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which modifies the disclosure and presentation requirements of reportable segments. This update is effective for the Company beginning with its fiscal year 2025 reporting and for interim reporting beginning with its fiscal year 2026. While this accounting standard will increase disclosures, it will not have a material impact on the Company’s Consolidated Financial Statements. In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to enhance the transparency and decision usefulness of income tax disclosures. This update is effective for the Company beginning with its fiscal year 2026 reporting. While this accounting standard will increase disclosures, it will not have a material impact on the Company’s Consolidated Financial Statements. In November 2024, the Financial Accounting Standards Board issued Accounting Standards Update 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40), to improve disclosures about an entity's expenses including more detailed information about the components of expenses in commonly presented expense captions. This update is effective for the Company beginning with its fiscal year 2028 reporting and for interim reporting beginning with its fiscal year 2029. While this accounting standard will increase disclosures, it will not have a material impact on the Company’s Consolidated Financial Statements.

Third Party Arrangements and Re

Third Party Arrangements and Related Party Disclosures	12 Months Ended
	Sep. 30, 2024
Third Party and Related Party Transactions [Abstract]
Third Party Arrangements and Related Party Disclosures	Note 4 — Third Party Arrangements and Related Party Disclosures Pursuant to the Separation, BD ceased to be a related party to Embecta and accordingly, no related party transactions or balances are reported subsequent to April 1, 2022. In connection with the Separation, the Company entered into the Separation and Distribution Agreement, which contains provisions that, among other things, relate to (i) assets, liabilities and contracts to be transferred, assumed and assigned to each of Embecta and BD (including certain deferred assets and liabilities) as part of the Separation, (ii) cross-indemnities principally designed to place financial responsibility for the obligations and liabilities of Embecta's business with Embecta and financial responsibility for the obligations and liabilities of BD’s remaining businesses with BD, (iii) procedures with respect to claims subject to indemnification and related matters, (iv) the allocation among Embecta and BD of rights and obligations under existing insurance policies with respect to occurrences prior to completion of the Separation, as well as the right to proceeds and the obligation to incur certain deductibles under certain insurance policies, and (v) procedures governing Embecta’s and BD’s obligations and allocations of liabilities with respect to ongoing litigation matters that may implicate each of BD’s business and Embecta’s business. Agreements that Embecta entered into with BD that govern aspects of Embecta's relationship with BD following the Separation include, but are not limited to: • Transition Services Agreements ("TSA") - Pursuant to the TSA, as amended, Embecta and BD and their respective affiliates provide each other, on an interim, transitional basis, various services, including, but not limited to, information technology, human resources, procurement, quality and regulatory affairs, medical affairs, tax and treasury services. The agreed-upon charges for such services are generally intended to allow the servicing party to charge a price comprised of out-of-pocket costs and expenses and a predetermined profit in the form of a mark-up of such out-of-pocket costs and expenses. Such services provided pursuant to the TSA were to terminate no later than April 1, 2024, 24 months following the Separation. On March 28, 2024, BD granted a limited extension until November 1, 2024 of certain services under the TSA and the Logistics Services Agreement (“LSA”) in a limited set of markets (the "Extension") to support the Interim Business Continuity Processes. • Trade Receivables Factoring Agreements - Embecta and BD entered into trade receivables factoring agreements (the "Factoring Agreements"), under which Embecta transferred certain net trade receivable assets to BD, and paid a service fee calculated as 0.1% of annual revenues related to countries subject to the Factoring Agreements in exchange for the services provided by BD. Per the terms of the Factoring Agreements, the Company and its relevant subsidiaries sold receivables to the corresponding BD subsidiary in the same jurisdiction and such BD subsidiary collected the receivables from Company's customers. The BD subsidiary assumed the credit risk in respect of the receivables, and accordingly deducted a factoring fee from the purchase price of such receivables. Accordingly, Embecta accounted for the transfer as sales of trade receivables by recognizing an increase to Cash and equivalents and a decrease to Trade Receivables, net in the Consolidated Balance Sheets when proceeds from the transactions are received. The transfers are presented in the Consolidated Statements of Cash Flows as operating activities and the related service fee is presented as a component of Other income (expense), net in the Consolidated Statements of Income. The Trade Receivables Factoring Agreements terminated and expired as of March 31, 2024. • Distribution Agreements - Embecta and BD entered into distribution agreements for certain territories, principally in the Asia Pacific Region and Latin America, whereby a subsidiary of BD was appointed as a distributor of Embecta or its relevant subsidiaries to support certain commercial operations of the diabetes care business on a transitional basis in these regions for a maximum of two years. The distribution agreements each continued until either (1) certain governmental approvals needed to distribute products in the defined territory are obtained and order-to-cash processes and other services of the Company for such territory are migrated to an alternative commercial arrangement between the parties or (2) the applicable services are transitioned to a third-party distributor or independently performed by Embecta, but in any event no longer than the maximum term of two years, except certain such agreements may be extended in connection with the Extension. All distribution agreements in the Asia Pacific Region and Latin America terminated and expired in October 2024. Embecta paid BD a return of 1.5% to 2.0% of net revenue for each territory. • Cannula Supply Agreement - Embecta and BD entered into a cannula supply agreement whereby BD sells to Embecta cannulas for incorporation into Embecta's existing syringes and pen needles, safety syringes and safety pen needles, and products currently under development. BD retains ownership of all cannula technology, cannula production activities and the intellectual property rights therein. Embecta is limited to a maximum number of cannulas that it can purchase under the cannula supply agreement, which will be an absolute upper limit of cannulas per year and yearly limits that vary with annual demand. The cannula supply agreement is terminable by Embecta without cause by providing at least 36 months’ written notice; however, such termination can be effective no earlier than five years from the Separation. The cannula supply agreement will be terminable by BD without cause by providing at least 36 months’ written notice; however, such termination can be effective no earlier than ten years from the Separation. However, in the event of a change of control of Embecta, BD has the right to terminate the cannula supply agreement in its sole discretion. The cannula supply agreement will also terminate automatically, subject to a 36-month wind-down period, if Embecta’s yearly forecast is below the required minimum purchase amount, and the parties have other customary termination rights for material breach or bankruptcy of the other party. • Tax Matters Agreement - Pursuant to the tax matters agreement, Embecta agreed to certain covenants that contain restrictions intended to preserve the tax-free status of the distribution and certain related transactions. Embecta may take certain actions prohibited by these covenants only if Embecta obtains and provides to BD an opinion from a United States tax counsel or accountant of recognized national standing, in either case satisfactory to BD, to the effect that such action would not jeopardize the tax-free status of the distribution and certain related transactions, or if Embecta obtains prior written consent of BD. Embecta is barred from taking any action, or failing to take any action, where such action or failure to act adversely affects or could reasonably be expected to adversely affect the tax-free status of the distribution and certain related transactions or result in certain other taxes to BD, for all relevant time periods. • Logistics Services Agreement - Embecta and BD entered into the LSA, as amended, whereby BD provides Embecta with certain order-to-cash and logistics services to support certain commercial operations for a maximum term of two years, which BD agreed to extend pursuant to the Extension. Embecta pays BD (i) reimbursable costs, including all shipping costs, selling costs, general administration costs, costs of goods, research and development services costs, and other income and expenses related solely to the diabetes care business, that are incurred by BD directly, as allocated costs or as costs payable to a third party and (ii) a monthly administrative fee of 1.0% of net revenue (which increased to 1.25% of net revenue after January 1, 2024). • Other agreements that Embecta entered into with BD include, but are not limited to, the employee matters agreement ("EMA"), an intellectual property matters agreement, local support services agreements, certain other manufacturing arrangements and a process services agreement and lease agreement for a manufacturing facility located in Holdrege, Nebraska. See Note 18 for more information on the lease agreement for Holdrege. As it pertains to the Distribution Agreements noted above, Embecta determined it was the principal under these arrangements and was entitled to all the benefits, and was liable for all the risks, related to the inventory and receivables. Additionally, Embecta had latitude in pricing, had the ability to direct BD regarding decisions over inventory, and was responsible for all credit and collections risks and losses associated with the related receivables when there was no factoring agreement in place. As such, Embecta recognized these sales on a gross basis. On March 28, 2024, the Company entered into (i) a second amendment (the “TSA Amendment”) to the TSA, dated as of March 31, 2022 and previously amended as of July 1, 2022 by and between Embecta and BD, and (ii) a second amendment (the “LSA Amendment”) to the LSA, dated January 1, 2022 and previously amended as of November 20, 2023, by and between Embecta and BD. Under the TSA Amendment and the LSA Amendment, BD granted Embecta, among other things, the Extension. As of March 31, 2024, all Factoring Agreements between Embecta and BD had expired and terminated as a result of the Company's implementation and onboarding of certain systems and services, including, but not limited to, information technology, procurement, quality and regulatory affairs, medical affairs, tax and treasury services, distribution logistics, and shared services infrastructure support for order-to-cash, source-to-pay, and record-to-report, which, for clarity, includes enterprise resource planning (“ERP”) systems (“Business Continuity Processes”) in North America, and certain jurisdictions in Europe and Asia. The amounts due from BD under the above agreements were $53.8 million and $10.9 million at September 30, 2024 and are reflected in Amounts due from Becton, Dickinson and Company and Trade receivables, net , respectively. The amount due to BD under these agreements was $42.5 million at September 30, 2024 and is included in Amounts due to Becton, Dickinson and Company . The closing of the transfers of certain assets and liabilities related to the Diabetes Care Business in certain jurisdictions, including Mexico, India, Brazil, and Colombia, as contemplated by the Separation and Distribution Agreement did not occur at Separation. The transfers of the relevant local assets and liabilities in Mexico, Brazil, and Colombia closed in October 2024. The transfer of the relevant local assets and liabilities in India are expected to close at a future date. As of September 30, 2024, the Company estimates that amounts due from BD related to certain assets and liabilities in these jurisdictions are $7.0 million and are reflected in Prepaid expenses and other . As of September 30, 2024, the Company estimates that amounts due to BD related to certain assets and liabilities in these jurisdictions is $6.3 million and are reflected in Accrued expenses . Prior to the Separation, the Company did not operate as a standalone business and the Consolidated Financial Statements were derived from the consolidated financial statements and accounting records of BD. The following disclosures summarize activity between the Company and BD up to the Separation, including the affiliates of BD that were not part of the Separation. Corporate and Medical Segment Allocations from BD Prior to the Separation, BD provided significant corporate, finance, human resources, information technology, facilities, and legal services, among others (collectively, “General Corporate Expenses”) to the Company. Some of these services continue to be provided by BD to the Company on a temporary basis under the TSA. For purposes of these Consolidated Financial Statements for the periods prior to the Separation, the General Corporate Expenses have been allocated to the Company. The allocations of General Corporate Expenses are reflected in the Consolidated Statements of Income as follows: Year ended September 30, 2022 Cost of products sold $ 2.3 Selling and administrative expense 47.9 Research and development expense 3.5 Other (income) expense, net (0.6) Total General Corporate Expenses $ 53.1 These expenses were allocated to the Company on a pro rata basis of global and regional revenues, headcount, research and development spend and other drivers. Management believes the assumptions underlying the Consolidated Financial Statements, including the assumptions regarding allocating General Corporate Expenses from BD, are reasonable. Nevertheless, the Consolidated Financial Statements for periods prior to the Separation may not include all of the actual expenses that would have been incurred and may not reflect the Company’s Consolidated results of operations, financial position and cash flows had it been a standalone public company during the periods presented. Actual costs that would have been incurred if the Company had been a standalone public company would depend on multiple factors, including organizational structure and strategic decisions made in various areas, including information technology and infrastructure. Related party transactions The following transactions represent activity in the ordinary course of business between the Company and BD prior to the Separation for certain materials for use in production of certain medical products that were not at arm’s length. The following table summarizes such former related party purchases as follows: Year ended September 30, 2022 Purchases from BD $ 28.0 All significant intercompany transactions between the Company and BD prior to the Separation have been included in the Consolidated Financial Statements and are considered to be effectively settled for cash at the time the transaction is recorded. For the period prior to the Separation, the total net effect of the settlement of these intercompany transactions is reflected in the Consolidated Statements of Cash Flows as a financing activity and in the Consolidated Balance Sheets as Net Investment from Becton, Dickinson and Company. Prior to the Separation, net transfers to BD were included within Net Investment from Becton, Dickinson and Company . in the Consolidated Statements of Equity and represent the net effect of transactions between the Company and BD. The following table summarizes the components of the net transfers to BD as follows: Year ended September 30, 2022 Cash pooling and general financing activities (1) $ 255.9 Corporate and segment allocations, excluding non-cash stock-based compensation (50.4) Taxes deemed settled with BD (16.2) Other Separation related adjustments, net (11.4) Net transfers to BD as reflected in the Consolidated Statements of Cash Flows 177.9 Share-based compensation expense (8.5) Pension expense (3.6) Net consideration paid to BD in connection with the Separation 1,266.0 Related party senior secured notes 197.0 Other transfers to (from) BD, net 84.1 Net transfers to BD $ 1,712.9 (1) The nature of activities includes financing activities for capital transfers, cash sweeps and other treasury services. As part of this activity, cash balances were swept to BD on a daily basis under the BD Treasury function and the Company receives capital from BD for its cash needs. Related Party Senior Secured Notes On March 31, 2022, Embecta issued $200.0 million of senior secured notes to BD (the "Related Party Notes"). The Related Party Notes issued to BD were not issued for cash and instead were subject to a debt-for-debt exchange which occurred on April 1, 2022. As of April 1, 2022 t he Related Party Notes were reclassified to Long-Term Debt in the Consolidated Balance Sheets as the Related Party Notes are third party debt for periods post Separation. Refer to Note 13 for further information.

Collaboration Agreement

Collaboration Agreement	12 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration Agreement	Note 5 — Collaboration Agreement In March 2023, the Company entered into a collaboration agreement with a third-party to develop and commercialize an interoperable automated glycemic controller ("iAGC") to complement the Company's insulin patch pump currently in development. The Company believes that both parties are active participants in the operating activities of the collaboration and exposed to certain risks and rewards depending on commercial success. The transaction included an upfront payment of $2.5 million for project costs, which was expensed to Research and development expense during the fiscal year ended September 30, 2023. On November 22, 2024, the Company's Board of Directors approved a plan to discontinue internal and external investment in the research and development of the Company's patch pump program. The Company will refocus its research and development strategy on its core business. For additional information related to this matter, refer to Note 21.

Other Operating Expenses

Other Operating Expenses	12 Months Ended
	Sep. 30, 2024
Other Income and Expenses [Abstract]
Other Operating Expenses	Note 6 — Other Operating Expenses In connection with the Separation, the Company incurred separation and stand-up costs of approximately $110.8 million , $92.7 million, and $44.7 million during the fiscal years ended September 30, 2024, 2023, and 2022, respectively. The costs incurred primarily consist of costs associated with accounting, auditing, legal services, marketing, supply chain, employee retention, the implementation of the Company's new ERP system, and certain other costs to establish certain Business Continuity Processes and stand-alone functions to assist with the transition to being a stand-alone entity. During the fiscal year ended September 30, 2024, the Company recognized $6.3 million of costs associated with the amortization of cloud computing arrangements. For the fiscal years ended September 30, 2023 and 2022, there were no amortization of implementation costs associated with cloud computing arrangements due to the timing of when these projects were placed into service. The Company recorded approximately $7.4 million and $5.6 million of severance costs related to the optimization of certain business functions during the fiscal years ended September 30, 2024, and 2023, respectively. These costs were primarily recorded in the U.S. and liabilities for costs associated with these activities were not material to any period presented. For the fiscal year ended September 30, 2022 severance costs were not material to the Company's Consolidated Statements of Income.

Contingencies

Contingencies	12 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 7 — Contingencies The Company is subject to potential liabilities under government regulations and various claims and legal actions that are pending or may be asserted from time-to-time. These matters arise in the ordinary course and conduct of the Company’s business and include, for example, commercial, product liability, breach of contract and tort, intellectual property, product liability, environmental, securities and employment matters. The Company intends to continue to defend itself vigorously in such matters and when warranted, take legal action against others. Furthermore, the Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. An estimated loss contingency is accrued in the Company’s Financial Statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on the Company’s assessment, it has adequately accrued an amount for contingent liabilities currently in existence. The Company does not accrue amounts for liabilities that it does not believe are probable. Litigation is inherently unpredictable, and unfavorable resolutions could occur. As a result, assessing contingencies is highly subjective and requires judgment about future events. The amount of ultimate loss may exceed the Company’s current accruals, and it is possible that its cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies.

Revenues

Revenues	12 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenues	Note 8 — Revenues The Company’s policies for recognizing revenue have not changed from those described in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2023. The Company sells syringes, pen needles and other products used in the management of diabetes which are primarily sold to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. End-users of the Company’s products include healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. Measurement of Revenues Payment terms extended to the Company’s customers are based upon commercially reasonable terms for the markets in which the Company’s products are sold. Because the Company generally expects to receive payment within one year or less from when control of a product is transferred to the customer, the Company does not generally adjust its revenues for the effects of a financing component. The Company’s allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of its trade receivables. Such estimated credit losses are determined based on historical loss experiences, customer specific credit risk, and reasonable and supportable forward-looking information, such as country or regional risks that are not captured in the historical loss information. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. The allowance for doubtful accounts for trade receivables is not material to the Company’s Consolidated Financial Statements. The Company’s gross revenues are subject to a variety of gross-to-net deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, chargebacks, sales discounts, and sales returns. Because these deductions represent estimates of the related obligations, judgment is required when determining the impact of these revenue deductions on gross revenues for a reporting period. Rebates provided by the Company are based upon prices determined under the Company’s agreements primarily with its end-user customers. Additional factors considered in the estimate of the Company’s variable consideration liability include the quantification of inventory that is either in stock at or in transit to the Company’s distributors, as well as the estimated lag time between the sale of product and the payment of corresponding variable consideration. The Company’s liability attributed to variable consideration at September 30, 2024 and September 30, 2023 was $149.6 million and $36.4 million, respectively. Sales deductions recorded as a reduction of gross revenues for the fiscal years ended September 30, 2024, 2023 and 2022 were $525.9 million, $411.1 million, and $336.4 million respectively. Disaggregation of Revenues Disaggregation of revenue by geographic region is provided within Note 9. Contract Assets and Liabilities The Company does not have contract liabilities. Contract assets consist of the Company’s right to consideration that is conditional upon its future performance pursuant to private label agreements and are presented within Prepaid expenses and other in the Consolidated Balance Sheets. The Company’s contract asset balance was $1.2 million as of each of September 30, 2024 and 2023.

Segment, Geographic, and Produc

Segment, Geographic, and Product Information	12 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Segment, Geographic, and Product Information	Note 9 — Segment, Geographic, and Product Information Operating segments are identified as components of an enterprise in which discrete financial information is available for evaluation by the CODM in making decisions regarding assessing business performance and allocating resources and capital. Management has concluded that the Company operates in one segment based upon the information used by the CODM in evaluating the performance of the Company’s business and allocating resources and capital. Disaggregation of Revenues The Company has distribution agreements with regional or national distributors (including wholesalers and medical suppliers) to ensure broad availability of its products as well as a direct sales force in certain countries and regions around the world. In the United States and Canada, the Company utilizes its large and small key account managers that call on payers, retailers, wholesalers and institutional customers, and field-based territory managers that call on health care providers and pharmacies. In certain markets within Europe, the Company has dedicated sales representatives and in certain regions of the Middle East and Africa, the Company has distribution agreements. In Asia, the Company has distribution agreements and in China, the Company relies on its own commercial team to support sales execution. In Latin America, the Company maintains distribution agreements and direct sales representatives. Revenues by geographic region are as follows: Year ended September 30, 2024 2023 2022 United States $ 607.2 $ 601.4 $ 600.3 International (1) 515.9 519.4 529.2 Total $ 1,123.1 $ 1,120.8 $ 1,129.5 (1) For the fiscal years ended September 30, 2024, 2023, and 2022 no individual country outside of the United States generated net revenues that represented more than 10.0% of total revenues. Revenues by product family are as follows: Year ended September 30, 2024 2023 2022 Pen Needles $ 844.4 $ 829.2 $ 824.6 Syringes 126.2 138.1 156.0 Safety 129.4 126.3 119.6 Other (1) 10.3 14.2 14.3 Contract Manufacturing 12.8 13.0 15.0 Total $ 1,123.1 $ 1,120.8 $ 1,129.5 (1) In 2024, Other includes product sales for swabs and other accessories. In 2024, Other also includes the recognition of incremental Italian payback accruals resulting from two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015 which totaled $4.1 million.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 10 — Stock-Based Compensation Periods Prior to Separation Prior to the Separation, certain of the Company's employees participated in stock-based compensation plans sponsored by BD. Under these plans BD granted time-vested restricted stock units ("TVUs"), stock appreciation rights ("SARs"), and performance share units ("PSUs") to certain management level employees. Prior to the Separation on April 1, 2022, share-based compensation expense in the Consolidated Statements of Income is representative of those employees who were dedicated to the Diabetes Care Business. Additionally, share-based compensation expense was allocated to the Diabetes Care Business for BD Corporate and Medical Segment employees who were not dedicated solely to the Diabetes Care Business. This stock-based compensation expense was allocated using a proportional cost allocation method and is included as a component of corporate allocations for periods prior to the Separation. The amounts presented for the periods prior to the Separation are not necessarily indicative of future awards and do not necessarily reflect the costs that the Company would have incurred as an independent company. As of Separation Date and Periods Post Separation In connection with the Separation, and in accordance with the EMA, Embecta's employees with outstanding former BD share-based awards received replacement share-based awards under the Plan. The ratio used to convert the BD share-based awards was designed to preserve the aggregate intrinsic value of the award immediately after the Separation when compared to the aggregate intrinsic value of the award immediately prior to Separation. As a result of the award modification, Embecta will incur $6.1 million of incremental stock-based compensation expense. Of this amount, $1.2 million, $1.8 million and $2.3 million was recognized during the fiscal years ended September 30, 2024, 2023 and 2022, respectively. $0.8 million will be recognized at a future date over the awards' remaining vesting period. Effective April 1, 2022, Embecta established the Plan, as amended on February 7, 2024. A total of 10,189,000 shares of common stock are authorized under the Plan. The Plan provides for the grant of various types of awards including RSU awards, SARs, stock options, performance-based awards, and other stock-based awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. Generally SARs have a term of ten years and a three The Company recognizes stock-based compensation cost only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants. The cumulative effect on current and prior periods of a change in the estimated forfeiture rate is recognized as compensation cost in earnings in the period of the change. Stock-Based Compensation Expense Total direct and allocated stock-based compensation expense for the fiscal years ended September 30, 2024, 2023, and 2022 and the respective income tax benefits recognized by the Company in the Consolidated Statements of Income are as follows: 2024 2023 2022 Cost of products sold $ 3.0 $ 2.2 $ 2.3 Selling and administrative expense 21.4 18.1 14.6 Research and development expense 2.2 1.6 1.8 Total Stock-Based Compensation Expense $ 26.6 $ 21.9 $ 18.7 Tax benefit associated with stock-based compensation costs recognized $ 3.2 $ 2.7 $ 2.9 The following table summarizes the Company's total stock-based compensation expense by classification of award: 2024 2023 2022 Equity Awards $ 26.3 $ 21.5 $ 18.7 Liability Awards 0.3 0.4 — Total $ 26.6 $ 21.9 $ 18.7 The following table summarizes the Company's total stock-based compensation expense by award type for the fiscal years ended September 30, 2024, 2023 and 2022, subsequent to the Separation: 2024 2023 2022 Time-Vested Restricted Stock Units (TVUs) $ 19.5 $ 16.2 $ 6.6 Performance-Based Restricted Stock Units (PSUs) 3.2 1.0 — Stock Appreciation Rights (SARs) 3.9 4.7 3.7 Total $ 26.6 $ 21.9 $ 10.3 Time Vested Restricted Stock Units During the fiscal year ended September 30, 2024 , Embecta granted 1,437,311 RSUs in the form of TVUs to employees which vest ratably over three years, subject to continued employment of the recipients. TVUs vest on a graded basis over a period of three years. The related stock-based compensation expense is recorded over the requisite service period, which is the vesting period or is based on retirement eligibility. The fair value of all TVUs is based on the market value of the Company’s stock on the date of grant. A summary of TVUs outstanding as of September 30, 2024 and changes during the fiscal year then ended is as follows: Stock Units (in thousands) Weighted Average Grant Date Fair Value Nonvested at October 1 1,188.8 $ 29.42 Granted 1,437.3 17.39 Distributed* (553.9) 28.41 Forfeited, canceled or expired (154.2) 21.29 Nonvested at September 30 1,918.0 $ 21.34 Expected to vest at September 30 1,823.1 $ 21.40 *The amounts distributed include shares withheld for taxes that are not formally issued to the market. The weighted average grant date fair value of TVUs granted during the fiscal years 2024, 2023 and 2022 are as follows: 2024 2023 2022 Weighted average grant date fair value of units granted $ 17.39 $ 31.00 $ 31.23 The total fair value of TVUs vested during the fiscal years 2024, 2023 and 2022 was as follows: 2024 2023 2022 Total fair value of units vested $ 15.7 $ 10.9 $ 1.6 At September 30, 2024, the weighted average remaining vesting term of TVUs is 1.6 years. Performance Based Restricted Stock Units During the fiscal year ended September 30, 2024 , Embecta awarded 553,235 RSUs in the form of PSUs to certain executive officers and employees which vest after three years, subject to continued employment of the recipients and the achievement of certain performance metric targets. The Company has identified certain performance metrics and targets that will be fully established at a future date. The Company has determined that the service inception date precedes the grant date for these awards as (a) the awards were authorized prior to establishing an accounting grant date, (b) the recipients began providing services prior to the grant date, and (c) there are performance conditions that, if not met by the accounting grant date, will result in the forfeiture of the awards. As the service inception date precedes the accounting grant date, the Company recognizes stock-based compensation expense for each separately-vesting tranche over the requisite service period based on the fair value at each reporting date. PSUs cliff vest on the third anniversary after grant date. The related stock-based compensation expense is recorded over the requisite service period, which is the vesting period or is based on retirement eligibility. The fair value of all PSUs is based on the market value of the Company’s stock on the date of grant. A summary of PSUs outstanding as of September 30, 2024 and changes during the fiscal year then ended is as follows: Stock Units (in thousands) Weighted Average Grant Date Fair Value Nonvested at October 1 57.8 $ 30.24 Forfeited, canceled or expired (1.1) 30.24 Nonvested at September 30 56.7 $ 30.24 Expected to vest at September 30 53.5 $ 30.24 The weighted average grant date fair value of PSUs granted during the fiscal year 2023 is as follows: 2023 Weighted average grant date fair value of units granted $ 30.24 At September 30, 2024, the weighted average remaining vesting term of PSUs is 1.2 years. Stock Appreciation Rights SARs represent the right to receive, upon exercise, shares of common stock having a value equal to the difference between the market price of common stock on the date of exercise and the exercise price on the date of grant. SARs generally vest over a period of three In connection with the SARs granted during 2022, the Company used the BSM to determine the fair value of the SARs as of the grant date. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its SARs. The expected dividend yield is based on forecasted patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon United States Treasury Notes with a term equal to the expected term of the SAR. Expected volatility is estimated using historical volatility. Due to the lack of trading history of Embecta's stock at the time of valuation efforts, the historical component of expected volatility is based on historical monthly price changes of the peer group within the industry. BD's historical data for Embecta employees was used to estimate equity award exercise and employee termination behavior within the valuation model. The expected term represents the amount of time that SARs granted are expected to be outstanding based on historical and forecasted exercise behavior. The weighted average fair value of SARs was determined using the following assumptions: 2022 Risk-free interest rate 2.5 % Expected volatility 37.8 % Expected dividend yield 2.9 % Expected life 6.5 Fair value per SAR $ 9.38 A summary of SARs outstanding as of September 30, 2024 and changes during the fiscal year then ended is as follows: SARs (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Balance at October 1 1,831.7 $ 29.06 Forfeited, canceled or expired (71.3) $ 27.70 Balance at September 30 1,760.4 $ 29.11 6.7 $ — Vested and expected to vest at September 30 1,709.7 $ 29.09 6.7 $ — Exercisable at September 30 838.8 $ 28.03 6.1 $ — A summary of SARs exercised during the fiscal years 2023 and 2022 is as follows: 2023 2022 Total intrinsic value of SARs exercised $ 0.3 $ 0.1 Total fair value of SARs exercised $ 0.6 $ 6.1 Unrecognized Compensation Expense and Other Stock Plans The amount of unrecognized compensation expense for all non-vested stock-based awards as of September 30, 2024, is approximately $29.5 million, which is expected to be recognized over a weighted-average remaining life of approximately 1.7 years. At September 30, 2024, 2.7 million shares were authorized for future grants under the Plan.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Note 11 — Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets consisted of: Weighted Average Amortization Period (Years) September 30, 2024 September 30, 2023 Amortized intangible assets Patents – gross 11.4 $ 10.8 $ 10.6 Less: accumulated amortization (5.1) (4.5) Patents – net $ 5.7 $ 6.1 Customer Relationships and Other – gross 4.8 $ 5.2 $ 5.4 Less: accumulated amortization (2.8) (2.4) Customer Relationships and Other – net $ 2.4 $ 3.0 Total amortized intangible assets $ 8.1 $ 9.1 Goodwill 15.6 15.6 Total Goodwill and Other Intangible Assets $ 23.7 $ 24.7 Intangible asset amortization expense was $1.1 million for the fiscal year ended September 30, 2024, $1.2 million for the fiscal year ended September 30, 2023 and $0.7 million for the fiscal year ended September 30, 2022, respectively. The estimated intangible asset amortization expense for each of the fiscal years ended September 30, 2025 through 2029 is expected to approximate $1.1 million per year and $2.8 million for fiscal years subsequent thereafter.

Cloud Computing Arrangements

Cloud Computing Arrangements	12 Months Ended
	Sep. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Cloud Computing Arrangements	Note 12 — Cloud Computing Arrangements Capitalized costs to implement cloud computing arrangements and accumulated amortization were as follows: September 30, 2024 September 30, 2023 Short-term portion $ 10.2 $ — Long-term portion 60.6 38.0 Total Capitalized implementation costs $ 70.8 $ 38.0 Less: accumulated amortization (6.3) — Total Capitalized implementation costs, net $ 64.5 $ 38.0 Costs amortized during the fiscal year ended September 30, 2024 were $6.3 million, and are included in Other operating expenses . For the fiscal years ended September 30, 2023 and 2022 there were no costs recognized related to the implementation of these cloud computing arrangements due to the timing of when these projects were placed into service. As of September 30, 2024, cloud computing arrangement assets in-service have remaining useful lives which range from approximately two

Long-Term Debt

Long-Term Debt	12 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Long-Term Debt	Note 13 — Long-Term Debt 5.00% Senior Secured Notes due 2030 On February 10, 2022 Embecta issued $500.0 million aggregate principal amount of 5.00% senior secured notes due February 15, 2030 (the “5.00% Notes”). Interest payments on the 5.00% Notes are due semi-annually in February and August until maturity . 6.75% Senior Secured Notes due 2030 On March 31, 2022, Embecta issued $200.0 million of 6.75% Related Party Notes at a discount of $3.0 million. The Related Party Notes issued to BD were not issued for cash and instead were subject to a debt-for-debt exchange which occurred on April 1, 2022. As such, the issuance of the Related Party Notes is a non-cash financing activity and is not presented in the Consolidated Statements of Cash Flows for the fiscal year ended September 30, 2022. On April 1, 2022, BD transferred the Related Party Notes with a notional value of $200.0 million issued by Embecta to Morgan Stanley in exchange for certain notes of BD that were purchased by Morgan Stanley pursuant to a tender offer. Morgan Stanley then sold the senior secured notes to qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act of 1933, as amended. As of April 1, 2022, the 6.75% senior secured notes (the "6.75% Notes") became third party debt of Embecta. Interest payments on the 6.75% Notes are due semi-annually in February and August until maturity. The 6.75% Notes will mature on February 15, 2030. Credit Agreement On March 31, 2022, Embecta entered into a credit agreement (the “Credit Agreement”), providing for: • a Term Loan B Facility (the "Term Loan") in the amount of $950.0 million, with a seven -year term that matures in March 2029. The interest rate is 300 basis points over the secured overnight financing rate (“SOFR”), with a 0.50% SOFR floor. The Term Loan was issued at a discount of 0.50%. Principal and interest payments on the Term Loan commenced on June 30, 2022. Such quarterly principal payments are calculated as 0.25% of the initial principal amount, with the remaining balance payable upon maturity. Per the terms of the Credit Agreement, the Company may from time to time voluntarily prepay the Term Loan in whole or in part without premium or penalty subject to certain exceptions. • a Revolving Credit Facility (the "Revolving Credit Facility") in an aggregate principal amount of up to $500.0 million, with a five -year term that matures in 2027. Borrowings under the Revolving Credit Facility bear interest, at Embecta’s option, at an annual rate equal to (a) in the case of loans denominated in United States dollars (i) the SOFR or (ii) the alternate base rate or (b) in the case of loans denominated in Euros, the EURIBOR rate, in each case plus an applicable margin specified in the credit agreement. A commitment fee applies to the unused portion of the Revolving Credit Facility, equal to 0.25% per annum. As of September 30, 2024, no amount has been drawn on the Revolving Credit Facility. The Credit Agreement and the senior secured notes are secured by substantially all assets of Embecta and each subsidiary guarantor, subject to certain exceptions. The Credit Agreement and the indentures for Embecta's outstanding 5.00% Notes and 6.75% Notes contain customary financial covenants, including a total net leverage ratio covenant, which measures the ratio of (i) consolidated total net debt to (ii) consolidated earnings before interest, taxes, depreciation and amortization, and subject to other adjustments, must meet certain defined limits which are tested on a quarterly basis in accordance with the terms of the Credit Agreement and the 5.00% Notes and 6.75% Notes. In addition, the Credit Agreement contains covenants that will limit, among other things, Embecta’s ability to prepay, redeem or repurchase its subordinated and junior lien debt, incur additional debt, make acquisitions, merge with other entities, pay dividends or distributions, redeem or repurchase equity interests, and create or become subject to liens. The following is a summary of Embecta's total debt outstanding as of September 30, 2024: Term Loan due March 2029 $ 901.3 5.00% Notes due February 2030 500.0 6.75% Notes due February 2030 200.0 Total principal debt issued $ 1,601.3 Less: current debt obligations (9.5) Less: debt issuance costs and discounts (26.5) Long-term debt $ 1,565.3 The debt issuance costs on the Term Loan, 5.00% Notes, 6.75% Notes and the discount on the Term Loan are reported in the Consolidated Balance Sheets as a reduction of debt and are amortized as a component of Interest expense, net over the term of the related debt using the effective interest method. In September 2024, the Company made a discretionary prepayment of $25.0 million on the Term Loan. Debt extinguishment charges as a result of this prepayment were not material to the Company's Consolidated Statements of Income. The Company made interest payments of $117.7 million related to its debt outstanding during the fiscal year ended September 30, 2024. The schedule of principal payments required on long-term debt for the next five fiscal years and thereafter is as follows: 2025 $ 9.5 2026 9.5 2027 9.5 2028 9.5 2029 863.3 Thereafter 700.0 Certain measures relating to our total debt outstanding as of September 30, 2024 were as follows: Total debt $ 1,574.8 Short-term debt as a percentage of total debt 0.6 % Weighted average cost of total debt 6.8 % The estimated fair value of long-term debt (including current portion) at September 30, 2024 was $1,527.3 million compared with a carrying value (which includes a reduction for unamortized debt issuance costs and discounts) of $1,574.8 million. Fair value was estimated using inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability and would be considered Level 2 in the fair value hierarchy.

Earnings per Share

Earnings per Share	12 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Earnings per Share	Note 14 — Earnings per Share The calculation of earnings per basic and diluted common share for the fiscal years ended September 30, 2024, 2023 and 2022 were as follows: ($ in millions and shares in thousands, except per share amounts) 2024 2023 2022 Net Income attributable to Embecta $ 78.3 $ 70.4 $ 223.6 Basic weighted average number of shares outstanding 57,681 57,248 57,024 Stock awards and equity units (share equivalent) 645 510 437 Diluted weighted average shares outstanding 58,326 57,758 57,461 Earnings per common share - Basic $ 1.36 $ 1.23 $ 3.92 Earnings per common share - Diluted $ 1.34 $ 1.22 $ 3.89 The computation of earnings per diluted share excludes the effect of the potential exercise of stock-based awards, when the effect of the potential exercise would be anti-dilutive. As of September 30, 2024, 2.8 million of dilutive share equivalents issuable under stock-based compensation plans were excluded from the diluted shares outstanding calculation because the result would have been antidilutive. As of both September 30, 2023 and September 30, 2022, 1.8 million of dilutive share equivalents issuable under stock-based compensation plans were excluded from the diluted shares outstanding calculation because the result would have been antidilutive.

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 15 — Income Taxes Income (Loss) Before Income Taxe s The components of Income Before Income Taxes for the fiscal years ended September 30 consisted of: 2024 2023 2022 Domestic $ (116.7) $ (100.9) $ (29.1) Foreign 160.9 206.6 285.7 Income before income taxes $ 44.2 $ 105.7 $ 256.6 Provision (benefit) for Income Taxes The provision (benefit) for income taxes for the fiscal years ended September 30 consisted of: 2024 2023 2022 Current: Federal $ 23.4 $ 2.6 $ 20.4 State 2.0 (0.8) 3.4 Foreign 11.1 19.2 35.7 $ 36.5 $ 21.0 $ 59.5 Deferred: Federal $ (44.1) $ 5.9 $ (31.1) State (4.6) 0.7 (4.6) Foreign (21.9) 7.7 9.2 $ (70.6) $ 14.3 $ (26.5) Income tax provision (benefit) $ (34.1) $ 35.3 $ 33.0 The Company's income tax provision for the first half of fiscal 2022 was prepared using a separate return method. The separate return method applies the accounting guidance for income taxes to the standalone financial statements as if the Company was a separate taxpayer and a standalone enterprise. The Company believes the assumptions supporting the allocation and presentation of income taxes on a separate return basis are reasonable. For a portion of fiscal year 2022, the Company’s domestic and foreign operations were included in BD’s domestic consolidated and foreign tax returns, and payments to all tax authorities were made by BD on the Company’s behalf. The Company filed its own foreign tax return and made its own foreign tax payments in Ireland. The Company’s current tax liabilities computed under the separate return method were considered to be effectively settled in the consolidated financial statements at the time the transaction was recorded, with the offset recorded against Net parent investment. Tax Rate Reconciliation A reconciliation of federal statutory tax rate to the Company's effective income tax rate was as follows: 2024 2023 2022 Federal statutory tax rate 21.0 % 21.0 % 21.0 % State and local income taxes, net of federal tax benefit (6.8) — (0.8) Foreign income tax at rates other than 21% (43.4) (17.3) (7.0) US tax on foreign earnings 2.7 12.5 0.2 Taxes on unremitted foreign earnings (40.6) 11.1 3.2 Tax reserves 14.5 (0.4) (1.8) Valuation allowances 41.9 14.0 — Tax credits (7.5) (1.5) (0.7) Tax law changes (65.0) — — Nontaxable items (12.2) (8.6) (1.1) Nondeductible expenses 16.5 2.5 — Other, net 1.8 0.1 (0.1) Effective income tax rate (77.1) % 33.4 % 12.9 % The decrease in the Company's effective income tax rate for fiscal year 2024 as compared to fiscal year 2023 was primarily due to a reduction in withholding taxes on unremitted earnings of foreign subsidiaries related to the expiration of a two-year stock holding period requirement in Switzerland, the recognition of deferred tax assets from Switzerland tax reform, changes in the geographical mix of earnings and overall lower pre-tax earnings; partially offset by an increase in uncertain tax positions and non-deductible expenses. The increase in the Company's effective income tax rate for fiscal year 2023 as compared to fiscal year 2022 was primarily due to the establishment of a valuation allowance against interest expense carryforwards in the U.S., an increase in U.S. tax on foreign earnings primarily because of limitations on the utilization of foreign tax credits and higher withholding taxes on unremitted foreign earnings; partially offset by increased tax benefits from non-taxable items and change in geographical mix of earnings. For fiscal year 2023, the Other, net included a tax benefit for the establishment of net deferred tax assets incurred in connection with the ongoing separation of the Diabetes Care Business from BD, partially offset by a return to provision adjustment from the prior fiscal year. Deferred Income Taxes Deferred income taxes at September 30 consisted of: 2024 2023 Deferred tax assets: Compensation and benefits $ 13.2 $ 9.7 Accruals and reserves 23.8 9.1 Intangibles 46.4 24.6 Property, plant and equipment 10.7 11.7 Capitalized research and development expenses 25.9 16.6 Leases 11.6 12.9 Deferred income 13.3 — Interest expense carryforwards 27.8 16.4 Tax loss and credit carryforwards 12.5 6.6 Other 5.9 2.1 Gross deferred tax assets before valuation allowance $ 191.1 $ 109.7 Valuation allowance $ (50.2) $ (31.6) Total deferred tax assets $ 140.9 $ 78.1 Deferred tax liabilities: Taxes on unremitted foreign earnings $ (1.9) $ (20.5) Right of use asset (12.1) (12.8) Capitalized cloud computing costs (10.7) — Total deferred tax liabilities $ (24.7) (33.3) Net deferred tax assets (liabilities) (i) $ 116.2 $ 44.8 i. Net deferred tax assets are included in Deferred Income Taxes and Other Assets and net deferred tax liabilities are included in Deferred Income Taxes and Other Liabilities in the Consolidated Balance Sheets. Deferred tax assets and liabilities are netted in the Consolidated Balance Sheets by separate tax jurisdictions. As of September 30, 2024 and September 30, 2023, the Company has recorded deferred taxes on undistributed earnings of its foreign subsidiaries. During fiscal year 2024, the Company recorded a tax benefit of approximately $16.8 million related to a reversal of taxes on unremitted foreign earnings due to the expiration of certain holding period requirements for stock ownership in its foreign affiliate. In addition, the Company recorded a tax benefit of approximately $28.7 million (before valuation allowance) related to the recognition of deferred tax assets for future amortization deductions and tax credits resulting from tax law changes in Switzerland. As of September 30, 2024, the Company has recorded valuation allowances of $50.2 million due to uncertainty that exists regarding the future realizability of certain deferred tax assets, primarily for interest expense carryforwards in the U.S. related to limitations on the annual deductibility of such interest, annual limitations on utilization of amortization deductions and tax credits in Switzerland, state tax credits and deferred tax assets related to certain foreign manufacturing operations As of September 30, 2023, the Company has recorded valuation allowances of $31.6 million due to the uncertainty that exists regarding future realizability of certain deferred tax assets primarily for interest expense carryforwards in the U.S. related to limitations on the annual deductibility of such interest, state net operating losses, state tax credits and deferred tax assets related to certain foreign manufacturing operations. The approximate tax benefit related to a tax holiday in Switzerland is $0.7 million and $0.01 impact on diluted earnings per share in fiscal year 2024. The Company will no longer receive tax benefits from the tax holiday beginning in 2025. As of September 30, 2024, the Company had tax loss and credit carryforwards of approximately $3.1 million of state income tax credit carryforwards, $6.3 million of Switzerland cantonal tax credit carryforwards and $3.1 million in net operating loss carryforwards in various jurisdictions. Approximately $0.3 million of net operating loss carryforwards will not expire and the remaining carryforwards expire in varying amounts from 2028 through 2044. Unrecognized Tax Benefits The table below summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled. 2024 2023 2022 Balance at October 1 $ 9.4 $ 5.7 $ 16.0 Increase due to current year tax positions 8.9 5.0 1.0 Increase due to prior year tax positions 2.1 3.7 — Decrease due to prior year tax positions (6.9) (0.3) (6.7) Decrease due to settlements with tax authorities — — — Decrease due to lapse of statute of limitations — (4.7) (4.6) Balance at September 30 $ 13.5 $ 9.4 $ 5.7 Unrecognized tax benefits including interest and penalties that would affect the effective tax rate if recognized $ 13.6 $ 7.2 $ 7.2 For a portion of fiscal year 2022, the Company’s domestic and foreign operations were included in BD’s domestic consolidated and foreign tax returns, with the exception of Ireland. The Company conducts business and files tax returns in numerous countries and currently has no tax audits in progress for the period after the Separation. The following were included for the fiscal years ended September 30 as a component of Income tax provision (benefit) in the Consolidated Statements of Income and the Consolidated Balance Sheets. 2024 2023 2022 Interest and penalties expense (benefit) associated with unrecognized tax benefits on the Consolidated Statements of Income $ — $ (1.2) $ (1.5) Interest and penalties associated with unrecognized tax benefits on the Consolidated Balance Sheets 0.1 0.2 1.5

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	12 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurements	Note 16 — Financial Instruments and Fair Value Measurements The following reconciles Cash and equivalents and Restricted cash reported within the Consolidated Balance Sheets as of September 30, 2024 and September 30, 2023, to the total amounts shown in the Consolidated Statements of Cash Flows: September 30, 2024 September 30, 2023 Cash and equivalents $ 267.5 $ 326.3 Restricted cash 6.7 0.2 Cash and equivalents and restricted cash $ 274.2 $ 326.5 Cash and equivalents includes cash held in money market funds and other cash equivalents. All cash and equivalents are Level 1 in the fair value hierarchy. Interest income on Cash and equivalents was $12.0 million and $9.4 million for the fiscal years ended September 30, 2024 and 2023, respectively, and is included as a component of Interest expense, net . For the fiscal year ended September 30, 2022, interest income was not material to the Company's Consolidated Statements of Income. Restricted cash consists of cash not readily available for use in the Company's operating activities. The Company's restricted cash balance is primarily pledged as collateral for bank guarantees related to certain customer performance guarantees and property leases internationally. Foreign Currency Risks and Related Strategies The Company has foreign currency exposures throughout Europe, Asia, Canada, and Latin America. Transactional currency exposures that arise from entering into transactions, generally on an intercompany basis, in non-hyperinflationary countries that are denominated in currencies other than the functional currency are mitigated primarily through the use of forward contracts. The notional amounts of the Company’s foreign currency-related derivative instruments were as follows: Hedge Designation September 30, 2024 September 30, 2023 Foreign exchange contracts (a) Undesignated $ 4.5 $ 6.7 a. Represent hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and receivables. Gains and losses on these instruments are recognized immediately in Other income (expense), net . These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Gains and losses recognized to date on these instruments were not material to the Company's Consolidated Financial Statements. Nonrecurring Fair Value Measurements Non-financial assets, including property, plant and equipment as well as intangible assets, are measured at fair value when there are indicators of impairment and these assets are recorded at fair value only when an impairment is recognized. These measurements of fair value are generally based upon Level 3 inputs, including values estimated using the income approach. During the fiscal year ended September 30, 2023, the Company recorded impairment charges of $2.5 million related to the abandonment of certain manufacturing equipment in China that is no longer in use that was inherited as part of the Separation from BD. These assets were previously included as a component of Machinery, equipment and fixtures within Property, Plant and Equipment . The impairment charges are recognized within Impairment expense in the Consolidated Statements of Income. During the fiscal year ended September 30, 2022, the Company recorded impairment charges of $58.9 million related to the abandonment of certain manufacturing production lines in the United States that are no longer expected to be completed. These assets were previously included as a component of Construction in progress within Property, Plant and Equipment . The impairment charges are recognized within Impairment expense in the Consolidated Statements of Income. Concentration of Credit Risk Three of the Company’s customers represented at least 10.0% of total gross revenues individually and, in the aggregate, represented approximately 41.3%, 40.2% and 40.1% for the fiscal years ended September 30, 2024, 2023 and 2022 respectively. One of the Company's customers represented at least 10.0% of total gross trade receivables individually and represented approximately 11.1% as of September 30, 2024.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Note 17 — Property, Plant and Equipment Property, Plant and Equipment, Net consisted of: As of September 30, 2024 As of September 30, 2023 Land $ 3.1 $ 2.3 Buildings 121.7 124.5 Machinery, equipment and fixtures 607.3 567.2 Leasehold improvements 11.9 9.1 Construction in progress 35.1 44.8 $ 779.1 $ 747.9 Less: accumulated depreciation (488.7) (447.7) Total Property, Plant and Equipment, Net $ 290.4 $ 300.2 During the fiscal year ended September 30, 2023, the Company recorded impairment charges of $2.5 million related to the abandonment of certain manufacturing equipment in China that is no longer in use that was inherited as part of the Separation from BD. These assets were previously included as a component of Machinery, equipment and fixtures within Property, Plant and Equipment . During the fiscal year ended September 30, 2022, the Company recorded impairment charges of $58.9 million related to the abandonment of certain manufacturing production lines in the United States that are no longer expected to be completed. These assets were previously included as a component of Construction in progress within Property, Plant and Equipment . The impairment charges are recognized within Impairment expense in the Consolidated Statements of Income.

Leases

Leases	12 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Leases	Note 18 — Leases Finance Lease In conjunction with the Separation, we entered into a lease agreement with BD pursuant to which the Company would lease approximately 278,000 square feet of manufacturing space and equipment at BD's manufacturing facility in Holdrege, Nebraska for an initial term of ten years and an option for the Company to extend the lease term for an additional period of up to five years. This lease is classified as a finance lease. Operating Leases The Company's operating leases primarily relate to its real estate leases that are not classified as finance leases. The Company entered into a real estate lease for a new Corporate Headquarters located in Parsippany, NJ which commenced during the second quarter of fiscal year 2023 for an initial term of ten years. The Company has options to extend the lease for additional period of six years and to extend for a subsequent additional period of four years, after the expiration of the first extension period. Aggregate Lease Information The Company's leases are included in its Consolidated Balance Sheets as follows: As of September 30, 2024 As of September 30, 2023 Finance Lease Property, Plant, and Equipment, Net $ 30.8 $ 33.1 Total Finance Lease Assets $ 30.8 $ 33.1 Current finance lease liabilities $ 3.4 $ 3.6 Non Current Finance Lease Liabilities 30.2 31.5 Total Finance Lease Liabilities $ 33.6 $ 35.1 Weighted-average remaining lease term (years) 12.5 13.5 Weighted-average discount rate 6.8 % 6.8 % Operating Leases Deferred Income Taxes and Other Assets $ 22.6 $ 23.0 Total Operating Lease Assets $ 22.6 $ 23.0 Accrued expenses $ 6.0 $ 5.9 Deferred Income Taxes and Other Liabilities 11.9 15.4 Total Operating Lease Liabilities $ 17.9 $ 21.3 Weighted-average remaining lease term (years) 6.3 7.3 Weighted-average discount rate 6.5 % 6.9 % Lease costs incurred are as follows: (in millions) Classification 2024 2023 Operating lease expense Selling and administrative and Research and Development expense $ 7.5 $ 4.5 Finance lease cost: Depreciation of lease assets Cost of products sold 2.5 2.4 Interest on lease liabilities Interest expense, net 2.4 2.4 Total lease cost $ 12.4 $ 9.3 For the fiscal year ended September 30, 2022, operating lease costs and finance lease costs were not material to the Company's Consolidated Statements of Income. Supplemental cash flow information related to leases was as follows as of September 30, 2024, 2023 and 2022: September 30, 2024 September 30, 2023 September 30, 2022 Right of use assets obtained in exchange for lease liabilities Finance Lease $ — $ — $ 36.7 Operating Leases 3.0 19.0 2.8 September 30, 2024 September 30, 2023 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from Operating Leases $ 6.4 $ 2.9 Financing cash flows from Finance Lease 1.3 1.2 Operating cash flows from Finance Lease 2.4 2.4 For the fiscal year ended September 30, 2022, cash paid for amounts included in the measurement of lease liabilities was not material. Maturities of the Company's finance and operating lease liabilities as of September 30, 2024 by fiscal year are as follows: Finance Leases Operating Leases Total 2025 3.7 6.2 9.9 2026 3.7 3.4 7.1 2027 3.8 1.8 5.6 2028 3.9 1.8 5.7 2029 3.9 1.7 5.6 Thereafter 32.3 7.3 39.6 Total lease payments $ 51.3 $ 22.2 $ 73.5 Less: amount representing interest 17.7 4.3 22.0 Present value of lease liabilities $ 33.6 $ 17.9 $ 51.5
Leases	Note 18 — Leases Finance Lease In conjunction with the Separation, we entered into a lease agreement with BD pursuant to which the Company would lease approximately 278,000 square feet of manufacturing space and equipment at BD's manufacturing facility in Holdrege, Nebraska for an initial term of ten years and an option for the Company to extend the lease term for an additional period of up to five years. This lease is classified as a finance lease. Operating Leases The Company's operating leases primarily relate to its real estate leases that are not classified as finance leases. The Company entered into a real estate lease for a new Corporate Headquarters located in Parsippany, NJ which commenced during the second quarter of fiscal year 2023 for an initial term of ten years. The Company has options to extend the lease for additional period of six years and to extend for a subsequent additional period of four years, after the expiration of the first extension period. Aggregate Lease Information The Company's leases are included in its Consolidated Balance Sheets as follows: As of September 30, 2024 As of September 30, 2023 Finance Lease Property, Plant, and Equipment, Net $ 30.8 $ 33.1 Total Finance Lease Assets $ 30.8 $ 33.1 Current finance lease liabilities $ 3.4 $ 3.6 Non Current Finance Lease Liabilities 30.2 31.5 Total Finance Lease Liabilities $ 33.6 $ 35.1 Weighted-average remaining lease term (years) 12.5 13.5 Weighted-average discount rate 6.8 % 6.8 % Operating Leases Deferred Income Taxes and Other Assets $ 22.6 $ 23.0 Total Operating Lease Assets $ 22.6 $ 23.0 Accrued expenses $ 6.0 $ 5.9 Deferred Income Taxes and Other Liabilities 11.9 15.4 Total Operating Lease Liabilities $ 17.9 $ 21.3 Weighted-average remaining lease term (years) 6.3 7.3 Weighted-average discount rate 6.5 % 6.9 % Lease costs incurred are as follows: (in millions) Classification 2024 2023 Operating lease expense Selling and administrative and Research and Development expense $ 7.5 $ 4.5 Finance lease cost: Depreciation of lease assets Cost of products sold 2.5 2.4 Interest on lease liabilities Interest expense, net 2.4 2.4 Total lease cost $ 12.4 $ 9.3 For the fiscal year ended September 30, 2022, operating lease costs and finance lease costs were not material to the Company's Consolidated Statements of Income. Supplemental cash flow information related to leases was as follows as of September 30, 2024, 2023 and 2022: September 30, 2024 September 30, 2023 September 30, 2022 Right of use assets obtained in exchange for lease liabilities Finance Lease $ — $ — $ 36.7 Operating Leases 3.0 19.0 2.8 September 30, 2024 September 30, 2023 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from Operating Leases $ 6.4 $ 2.9 Financing cash flows from Finance Lease 1.3 1.2 Operating cash flows from Finance Lease 2.4 2.4 For the fiscal year ended September 30, 2022, cash paid for amounts included in the measurement of lease liabilities was not material. Maturities of the Company's finance and operating lease liabilities as of September 30, 2024 by fiscal year are as follows: Finance Leases Operating Leases Total 2025 3.7 6.2 9.9 2026 3.7 3.4 7.1 2027 3.8 1.8 5.6 2028 3.9 1.8 5.7 2029 3.9 1.7 5.6 Thereafter 32.3 7.3 39.6 Total lease payments $ 51.3 $ 22.2 $ 73.5 Less: amount representing interest 17.7 4.3 22.0 Present value of lease liabilities $ 33.6 $ 17.9 $ 51.5

Benefit Plans

Benefit Plans	12 Months Ended
	Sep. 30, 2024
Retirement Benefits [Abstract]
Benefit Plans	Note 19 — Benefit Plans Defined Benefit Plans Prior to the Separation on April 1, 2022, Embecta participated in BD's non-United States plans. BD has defined benefit pension plans covering eligible employees in certain of its international subsidiaries. The Company participated in BD's benefit plans as though it was a participant in a multi-employer plan with the other businesses of BD. The retirement benefits accounting guidance provides that liabilities beyond any contributions currently due and unpaid are not required to be reported. For the period prior to the Separation, the Consolidated Statements of Income include expense allocations for these benefits, which were determined using a proportional allocation method. Total benefit plan expense allocated to the Company for the fiscal year ended September 30, 2022 was $3.6 million. Except for deferred closing countries, the Company's participation in the defined pension and postretirement benefit plans sponsored by BD concluded upon the completion of the Separation on April 1, 2022. As of April 1, 2022, Embecta became the plan sponsor for certain global defined benefit pension plans. These Consolidated Financial Statements reflect the periodic benefit costs and funded status of such plans. The Company uses September 30 as the year-end measurement date. Of the plans, the defined benefit pension plan covering employees in Switzerland (the "Swiss Plan") is the only defined benefit pension plan material to the Company's Consolidated Financial Statements. The Company's Swiss Plan is a government-mandated retirement account balance plan. Companies within the Swiss regulatory environment have substantial freedom in setting their pension plan design (e.g. with regards to the salary covered, level of retirement benefits, or overall benefit design) provided the benefits are always at least equal to the minimum requirements as defined by law. Most employers provide higher benefits than those required by law, which is the case for Embecta. The minimum level of retirement benefit is expressed by a cash balance formula with age-related contribution rates (or "retirement credits") based on an insured salary defined by law, and a minimum required interest crediting rate which is set by the government (1.25% in 2024, and 1.00% in 2023 and 2022). The sum of the Company's contributions should be at least equal to the sum of employee contributions. Contributions to the Swiss Plan are invested into a diversified fund managed by an investment fiduciary. As of September 30, 2024 and 2023, the Swiss plan had an unfunded net pension obligation of $4.0 million and $1.9 million, respectively, and plan assets that totaled $18.4 million, and $14.1 million, respectively. Net periodic benefit cost was not material to the Company's Consolidated Statements of Income for any period presented. Defined Contribution Plans The Company has various defined contribution savings plans that cover substantially all employees in the United States, Ireland, and Japan. The Company matches a certain percentage of each employee’s contributions as per the provisions of the plans. Total employer contributions by the Company to the plans were $15.1 million, $14.1 million and $8.9 million for the fiscal years ended September 30, 2024, 2023 and 2022, respectively. Between April 1, 2022 and September 30, 2022, BD remained the defined benefit pension plan sponsor for certain Embecta employees in Ireland. The Company accounts for this plan as though it was a participant in a multi-employer plan with other businesses of BD. The amount of contributions to BD for this plan are included in the amounts noted above. At the Separation Date, Embecta effectuated an Embecta sponsored defined contribution pension plan for certain other employees in Ireland. On October 1, 2022, any Embecta employees who remained participating in the BD defined benefit pension plan ceased participating and these employees began participating in an Embecta sponsored defined contribution pension plan that was effectuated at the Separation Date. Deferred Compensation Plan On the date of the Separation, the Company established a Deferred Compensation Plan in which certain directors and employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation. A participant's deferrals are “invested” at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator. The amounts accrued under this plan were $10.0 million and $6.1 million as of September 30, 2024 and 2023, respectively.

Supplemental Financial Informat

Supplemental Financial Information	12 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Financial Information	Note 20 — Supplemental Financial Information Trade Receivables, Net The amounts recognized in fiscal years 2024, 2023 and 2022 relating to allowances for doubtful accounts and cash discounts, which are netted against trade receivables, are provided in the following table: Allowance for Doubtful Accounts Allowance for Cash Discounts Total Balance at September 30, 2021 (3.1) (3.1) (6.2) Additions charged to costs and expenses (0.3) (18.1) (18.4) Deductions and other 2.1 (b) 21.1 23.2 Balance at September 30, 2022 (1.3) (0.1) (1.4) Additions charged to costs and expenses (0.2) (18.7) (18.9) Deductions and other 0.5 (a) 18.8 19.3 Balance at September 30, 2023 (1.0) — (1.0) Additions charged to costs and expenses (2.2) (17.5) (19.7) Deductions and other 0.4 (a) (3.6) (3.2) Balance at September 30, 2024 (2.8) (21.1) (23.9) (a) Accounts written off (b) Amounts factored to BD Long-Lived Assets Long-lived assets, which include Property, Plant and Equipment, net , and Goodwill and Other Intangibles, net, by geographic area where located at September 30, 2024 and 2023 is as follows: 2024 2023 United States $ 105.0 $ 109.2 Europe, Middle East, and Africa 170.8 176.9 Asia 37.2 38.4 Other 1.1 0.4 $ 314.1 $ 324.9

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 21 — Subsequent Events Discontinuation of the patch pump program On November 22, 2024, the Company’s Board of Directors approved a plan to discontinue internal and external investment in the research and development of the Company's patch pump program. The Company will refocus its investment on its core business while looking to optimize free cash flow and strengthen its balance sheet by paying down debt. As a result of this decision, the Company will undergo an organizational restructuring (the "Restructuring Plan"). In addition, the Company intends to discontinue its plans to manufacture and commercialize the insulin delivery system, including the previous intended limited launch. The Company estimates that it will incur approximately $25 million - $30 million in pre-tax cash-based charges primarily associated with employee severance payments and benefits related to the workforce reduction. The Company expects that the majority of the restructuring charges related to the workforce reduction will be incurred in the first quarter of fiscal 2025 and that the implementation of the workforce reduction, including cash payments, will be substantially complete by the end of the second quarter of fiscal 2025. The Company estimates that it will incur approximately $10 million - $15 million of additional pre-tax non-cash charges related to asset impairments and asset write-offs. These preliminary estimates may be revised following the completion of the ongoing analysis of the expected additional pre-tax non-cash charges associated with the implementation of the Restructuring Plan. The estimates of the pre-tax cash charges and additional charges that the Company expects to incur in connection with the Restructuring Plan, and the timing thereof, are subject to a number of assumptions and actual amounts may differ materially from estimates. In addition, the Company may incur other pre-tax cash charges or additional charges not currently contemplated due to unanticipated events that may occur, including in connection with the implementation of the Restructuring Plan. Performance-Based and Time-Vested Restricted Stock Units In November 2024 and pursuant to the Plan, the Company granted approximately 1.4 million TVUs in connection with the Company's annual grant which vest on a graded basis over a period of three years, subject to continuous service to the Company by the employee. The Company also awarded approximately 0.5 million PSUs to certain executive officers and employees in connection with the Company's annual grant which vest after three years, subject to continued employment of the recipients and the achievement of certain performance metric targets. The Company has identified certain performance metrics and targets that will be fully established at a future date. The Company has determined that the service inception date precedes the grant date for these awards as (a) the awards were authorized prior to establishing an accounting grant date, (b) the recipients began providing services prior to the grant date, and (c) there are performance conditions that, if not met by the accounting grant date, will result in the forfeiture of the awards.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net Income	$ 78.3	$ 70.4	$ 223.6

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Sep. 30, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Summary of Accounting Policies

Summary of Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Reclassifications	On April 1, 2022, the Company became a standalone publicly traded company, and its financial statements are now presented on a consolidated basis. Prior to the Separation on April 1, 2022, the Company’s historical combined financial statements were prepared on a standalone basis and were derived from BD's consolidated financial statements and accounting records. The financial statements for all periods presented, including the historical results of the Company prior to April 1, 2022, are now referred to as "Consolidated Financial Statements", and have been prepared pursuant to the rules and regulations for reporting on Form 10-K. Periods Prior to Separation Prior to the Separation, the Company was referred to as the Diabetes Care Business. The assets, liabilities, revenue and expenses of the Diabetes Care Business were reflected in the combined financial statements on a historical cost basis, as included in the consolidated financial statements of BD, using the historical accounting policies applied by BD. The Consolidated Financial Statements did not purport to reflect what the Company’s results of operations, comprehensive income, financial position, equity or cash flows would have been had the Company operated as a standalone public company during the periods presented. The Diabetes Care Business had historically functioned together with the other businesses controlled by BD. Accordingly, the Diabetes Care Business relied on BD’s corporate and other support functions for its business. Therefore, for the period prior to the Separation, certain corporate and shared costs were allocated to the Diabetes Care Business based on a specific identification basis or, when specific identification was not practicable, a proportional cost allocation method, including: i. expenses related to BD support functions, including expenses for facilities, executive oversight, treasury, finance, legal, human resources, shared services, compliance, procurement, information technology and other corporate functions. ii. certain manufacturing and supply costs incurred by BD, including facility management, distribution, logistics, planning and global quality. iii. certain costs incurred by BD’s Medication Delivery Solutions organizational unit in relation to selling and marketing activities, and related administrative support functions. iv. certain costs incurred by BD for activities related to device research and development, as well as medical and regulatory affairs. v. stock-based compensation expenses (see Note 10). vi. certain compensation expenses maintained on a centralized basis such as certain employee benefit expenses. Management believes these cost allocations were a reasonable reflection of the utilization of services provided to, or the benefit derived by, the Diabetes Care Business during the period prior to the Separation, though the allocations may not be indicative of the actual costs that would have been incurred had the Diabetes Care Business operated as a standalone public company. Actual costs that may have been incurred if the Diabetes Care Business had been a standalone company would depend on a number of factors, including the chosen organizational structure, whether functions were outsourced or performed by Diabetes Care Business employees, and strategic decisions made in areas such as manufacturing, selling and marketing, research and development, information technology and infrastructure. BD utilized a centralized approach to cash management and the financing of its operations. Cash generated by the Diabetes Care Business was routinely transferred into accounts managed by BD’s centralized treasury function and cash disbursements related to operations prior to the Separation were funded as needed by BD. Balances held by the Diabetes Care Business with BD for cash transfers and loans were reflected as Amounts due to Becton, Dickinson and Company prior to the Separation. All other cash and equivalents and related transfers between BD and the Diabetes Care Business were generally held centrally through accounts controlled and maintained by BD and were not specifically identifiable to the Diabetes Care Business. Accordingly, such balances were accounted for through Net Investment from Becton, Dickinson and Company . BD’s third-party debt and related interest expense were not attributed to the Diabetes Care Business because the business was not the legal obligor of the debt and the borrowings were not specifically identifiable to the business.
Consolidation	For the Diabetes Care Business, transactions with BD affiliates were included in the Consolidated Statements of Income and related balances were reflected as Amounts due to Becton, Dickinson and Company or Amounts due from Becton, Dickinson and Company . Other balances between the Diabetes Care Business and BD were considered to be effectively settled in the Consolidated Financial Statements at the time the transactions were recorded. As the separate legal entities that made up the Diabetes Care Business were not historically held by a single legal entity, Net Investment from Becton, Dickinson and Company was shown in lieu of stockholders’ equity in these Consolidated Financial Statements. Net Investment from Becton, Dickinson and Company represented BD’s interest in the recorded assets of the Diabetes Care Business and the cumulative investment by BD through the date of the Separation, inclusive of operating results. For periods prior to the Separation, income tax expense and tax balances in the Consolidated Financial Statements were calculated on a separate tax return basis. The separate tax return method applies the accounting guidance for income taxes to the standalone financial statements as if the Company was a separate taxpayer and a standalone enterprise. Management believes the assumptions supporting the allocation and presentation of income taxes on a separate return basis are reasonable. The provision for income taxes for the period prior to the Separation was calculated by applying an estimated effective income tax rate for the full year to ordinary income adjusted by the tax impact of discrete items. As of the Separation Date Certain assets and liabilities, including patents and unrecognized tax benefits that were included in the Consolidated Balance Sheet prior to the Separation, have been retained by BD post-Separation and therefore were transferred to BD through Net Investment from Becton, Dickinson and Company in the Company's Consolidated Financial Statements. In connection with the Separation, additional pension assets, deferred tax assets, other compensation obligations, and certain other assets and liabilities were transferred to the Company through Net Investment from Becton, Dickinson and Company , and the Company recorded these in the Consolidated Balance Sheet. As part of the Separation, Net Investment from Becton, Dickinson and Company was reclassified as Common Stock and Accumulated Deficit . Periods Post Separation Following the Separation, certain functions continue to be provided by BD under the Transition Services Agreements or are being performed using Embecta’s own resources or third-party service providers. Additionally, under manufacturing and supply agreements, the Company manufactures certain products for BD, or its applicable affiliate and BD manufactures certain products for the Company. The Company incurred certain costs in its establishment as a standalone public company and expects to incur ongoing additional costs associated with operating as an independent, publicly traded company. All intercompany transactions and accounts within Embecta have been eliminated.
Revenue Recognition and Measurement of Revenues	Revenue Recognition The Company recognizes revenue from product sales and considers performance obligations satisfied when the customer obtains control of the product, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. The Company acts as the principal in its customer arrangements and therefore records revenue on a gross basis. When arrangements include multiple performance obligations, the total transaction price of the contract is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. The point in time upon which shipment or delivery occurs is the most faithful depiction of when control of the goods transfers to the customer. Variable consideration such as rebates, chargebacks, sales discounts, and sales returns are estimated and treated as a reduction of revenue in the same period the related revenue is recognized. These estimates are based on contractual terms, historical practices and current trends, and are adjusted as new information becomes available. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. Measurement of Revenues Payment terms extended to the Company’s customers are based upon commercially reasonable terms for the markets in which the Company’s products are sold. Because the Company generally expects to receive payment within one year or less from when control of a product is transferred to the customer, the Company does not generally adjust its revenues for the effects of a financing component. The Company’s allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of its trade receivables. Such estimated credit losses are determined based on historical loss experiences, customer specific credit risk, and reasonable and supportable forward-looking information, such as country or regional risks that are not captured in the historical loss information. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. The allowance for doubtful accounts for trade receivables is not material to the Company’s Consolidated Financial Statements.
Cash and Equivalents	Cash and Equivalents Cash and equivalents include all highly liquid investments with a maturity of three months or less at the date of acquisition. Interest income on Cash and equivalents is recorded as earned.
Restricted Cash	Restricted Cash Restricted cash consists of cash not readily available for use in the Company's operating activities and is primarily pledged as collateral for bank guarantees related to certain customer performance guarantees and property leases internationally, which are further discussed in Note 16.
Trade Receivables	Trade Receivables The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The allowance for doubtful accounts represents the Company’s estimate of probable credit losses relating to trade receivables and is determined based on historical experience, current conditions, reasonable and supportable forecasts and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible.
Inventories	Inventories Inventories are stated at the lower of approximate cost or net realizable value determined on the first-in, first-out basis.
Cloud Computing Arrangements	Cloud Computing Arrangements The Company capitalizes costs incurred to implement cloud computing arrangements that are service contracts within Prepaid expenses and other and Deferred Income Taxes and Other Assets
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is principally provided on the straight-line basis over estimated useful lives, which range from 20 to 45 years for buildings, 4 to 13 years for machinery and equipment and 1 to 20 years for leasehold improvements. Depreciation expense was $34.9 million in 2024, $31.5 million in 2023, and $31.0 million in 2022. Property, plant and equipment are periodically reviewed when impairment indicators are present to assess recoverability or a decision has been made to abandon efforts associated with construction in progress assets. Recoverability is determined by comparing the carrying values of the assets or asset groups to the undiscounted cash flows to be generated from the use and eventual disposition of such assets or asset groups. If the asset’s or asset group’s carrying value exceeds such undiscounted cash flows, the assets or asset groups are not recoverable and an impairment loss is recognized based on the amount by which the carrying value of the asset or asset group exceeds its calculated fair value.
Capitalized Interest	Capitalized Interest The interest cost on capital projects is capitalized and included in the cost of the project. Capitalization commences with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use. When no debt is incurred specifically for a project, interest is capitalized on project expenditures using the weighted average cost of the Company's outstanding borrowings. For the fiscal years ended September 30, 2024, 2023 and 2022 the Company capitalized $3.7 million, $4.6 million and $5.2 million of interest expense, respectively, into Property, Plant and Equipment, Net . For the fiscal year ended September 30, 2023 the Company capitalized $0.9 million of interest expense into Deferred Income Taxes and Other Assets. Interest expense capitalized into Deferred Income Taxes and Other Assets during the fiscal year ended September 30, 2024 is not material to the Company’s Consolidated Financial Statements.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred and included in S elling and administrative expense
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. The Company has one reporting unit. Goodwill is evaluated for impairment as of July 1 each year, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that fair value is less than carrying value. If the Company concludes it is more likely than not that fair value is less than carrying value, a quantitative fair value test is performed. If carrying value is greater than fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill). The Company completed the annual goodwill impairment test as of July 1, 2024 and concluded that no impairment to goodwill was necessary as the fair value of the Company's one reporting unit was significantly in excess of the carrying value. No goodwill impairments were identified during the fiscal years ended September 30, 2024, 2023, or 2022, and no accumulated impairment losses are recorded. Amortized intangible assets primarily consist of patents and customer relationships. Patents are generally amortized over 20 years using the straight-line method. Customer relationship assets are generally amortized over periods ranging from 10 to 15 years, using the straight-line method. Other intangibles with finite useful lives are amortized over periods principally ranging from 1 to 40 years, using the straight-line method. Finite-lived intangible assets are periodically reviewed when impairment indicators are present to assess recoverability from future operations using undiscounted cash flows. The carrying values of these finite-lived assets are compared to the undiscounted cash flows they are expected to generate and an impairment loss is recognized in operating results to the extent any finite-lived intangible asset’s carrying value exceeds its calculated fair value.
Foreign Currency	Foreign Currency and Derivative Financial Instruments Assets and liabilities denominated in their functional currencies are translated into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates of exchange prevailing during the period. The United States dollar results that arise from such translation are included in Accumulated other comprehensive loss .
Derivative Financial Instruments	The Company utilizes derivative instruments to manage market risks associated with fluctuations in certain foreign currency exchange rates. The Company utilizes foreign currency forward contracts to protect against market risks arising in the normal course of business. At the end of the reporting period, foreign-currency-denominated assets and liabilities are remeasured into the functional currencies of the reporting entities at current market rates. The change in value from this remeasurement is reported as a foreign exchange gain or loss for that period in Other income (expense), net .
Shipping and Handling Costs	Shipping and Handling Costs
Contingencies	Contingencies
Stock-Based Compensation	Stock-Based Compensation Prior to the Separation, certain of the Company’s employees historically participated in BD’s stock-based compensation plans. Stock-based compensation expense was either allocated to the Company based on a proportionate cost allocation method or recorded based on specific identification. Effective April 1, 2022, the Company established the 2022 Employee and Director Equity Based Compensation Plan, as amended on February 7, 2024 (the "Plan"). The Plan provides for the grant of various types of awards, including restricted stock unit ("RSU") awards, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and generally may not be less than the fair market value per share on that date. The Company measures stock-based compensation for equity awards at fair value on the date of grant and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards. For awards that ultimately settle in cash, we treat them as liability awards and mark the award to market each reporting period and recognize any adjustment in our Consolidated Statements of Income. The Company recognizes stock-based compensation cost only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants. The cumulative effect on current and prior periods of a change in the estimated forfeiture rate is recognized as compensation cost in earnings in the period of the change (see Note 10).
Benefit Plans	Benefit Plans Prior to the Separation, the defined benefit plans in which the Company participated related primarily to plans sponsored by BD and for which other businesses of BD also participate (the "Shared Plans"). The Company accounted for the Shared Plans as multiemployer plans and therefore the related assets and liabilities were not reflected in the Consolidated Balance Sheets. For such periods prior to the Separation, the Consolidated Statements of Income reflect a proportional allocation of net periodic benefit cost for the Shared Plans associated with the Company. The Company's participation in the defined pension and postretirement benefit plans sponsored by BD concluded upon the completion of the Separation on April 1, 2022. At and after Separation, Embecta became the plan sponsor for certain non-United States defined benefit pension plans (see Note 19).
Research and Development	Research and Development Research and development costs are expensed as incurred.
Income Taxes	Income Taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax basis of assets and liabilities at the applicable tax rates. The Company maintains valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances are included in the tax provision in the period of change. In determining whether a valuation allowance is warranted, the Company evaluates factors such as prior earnings history, expected future earnings, carryback and carryforward periods, and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. From time to time, the Company engages in transactions in which tax consequences may be subject to uncertainty. The Company conducts business and files tax returns in numerous jurisdictions based on its interpretation of tax laws and regulations. In evaluating the Company’s tax provision, the Company establishes a reserve for uncertain tax positions unless such positions are determined to be more likely than not of being sustained upon examination based on the technical merits. The Company’s policy is to recognize, when applicable, interest and penalties on uncertain tax positions as part of income tax expense. While the Company believes it has identified all reasonable exposures and the reserve it has established is appropriate under the circumstances, it is possible that additional exposures exist and that exposures may be settled at amounts different than the amounts reserved. It is also possible that changes in facts and circumstances could cause the Company to either materially increase or reduce the carrying amount of its tax reserve. The Tax Cuts and Jobs Act was enacted on December 22, 2017 and introduced an additional United States tax on the earnings of non-United States subsidiaries which are referred to as Global Intangible Low Taxed Income (“GILTI”). The Company has elected to treat GILTI as a period cost. Prior to the Separation, the Company's operations were included in the tax returns of BD. Income taxes as presented in the Consolidated Financial Statements attribute current and deferred income tax assets and liabilities of BD to the Company in a manner that is systematic, rational, and consistent with the asset and liability method prescribed by the accounting guidance for income taxes. The Company's income tax provision prior to the Separation was prepared using the separate return method. The separate return method applies the accounting guidance for income taxes to the standalone financial statements as if the Company were a separate taxpayer and a standalone enterprise. The Company believes the assumptions supporting the allocation and presentation of income taxes on a separate return basis are reasonable.
Segment Data	Segment Data The Company operates and reports its financial information as one segment. In making this determination, the Company (i) determines its Chief Operating Decision Maker (“CODM”), (ii) identifies and analyzes potential business components, (iii) identifies its operating segments and (iv) determines whether there are multiple operating segments requiring presentation as reportable segments. The Company’s decision to report as one segment is based upon the following: (1) its internal organizational structure; (2) the manner in which its operations are managed; and (3) the criteria used by the Company’s President, its CODM, to evaluate performance of the Company’s business and allocate resources and capital.
Fair Value Measurements	Fair Value Measurements A fair value hierarchy is applied to prioritize inputs used in measuring fair value. The three levels of inputs used to measure fair value are detailed below. Additional disclosures regarding the Company’s fair value measurements are provided in Note 16. Level 1—Inputs to the valuation methodology which represent unadjusted quoted prices in active markets for identical assets and liabilities. Level 2—Inputs to the valuation methodology which include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3—Inputs to the valuation methodology which are unobservable and significant to the fair value measurement.
Leases	Leases The Company determines whether an arrangement contains a lease at inception. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability in the Company's Consolidated Balance Sheets and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12 months. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to Embecta by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that the Company is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases. Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the implicit rate is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease. For lease arrangements that are recognized on the Company’s Consolidated Balance Sheets, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain the Company will exercise the option. Finance leases are recorded in Property, Plant and Equipment, Net , Current finance lease liabilities , and Non Current Finance Lease Liabilities and operating leases are recorded in Deferred Income Taxes and Other Assets , Accrued expenses , and Deferred Income Taxes and Other Liabilities in the Company's Consolidated Balance Sheets.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates or assumptions affect reported assets, liabilities, revenues and expenses, including
Recently Issued Accounting Standards Not Yet Adopted	Recently Issued Accounting Standards Not Yet Adopted In November 2023, the Financial Accounting Standards Board issued Accounting Standards Update ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which modifies the disclosure and presentation requirements of reportable segments. This update is effective for the Company beginning with its fiscal year 2025 reporting and for interim reporting beginning with its fiscal year 2026. While this accounting standard will increase disclosures, it will not have a material impact on the Company’s Consolidated Financial Statements. In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to enhance the transparency and decision usefulness of income tax disclosures. This update is effective for the Company beginning with its fiscal year 2026 reporting. While this accounting standard will increase disclosures, it will not have a material impact on the Company’s Consolidated Financial Statements. In November 2024, the Financial Accounting Standards Board issued Accounting Standards Update 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40), to improve disclosures about an entity's expenses including more detailed information about the components of expenses in commonly presented expense captions. This update is effective for the Company beginning with its fiscal year 2028 reporting and for interim reporting beginning with its fiscal year 2029. While this accounting standard will increase disclosures, it will not have a material impact on the Company’s Consolidated Financial Statements.

Third Party Arrangements and _2

Third Party Arrangements and Related Party Disclosures (Tables)	12 Months Ended
	Sep. 30, 2024
Third Party and Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The allocations of General Corporate Expenses are reflected in the Consolidated Statements of Income as follows: Year ended September 30, 2022 Cost of products sold $ 2.3 Selling and administrative expense 47.9 Research and development expense 3.5 Other (income) expense, net (0.6) Total General Corporate Expenses $ 53.1 Year ended September 30, 2022 Purchases from BD $ 28.0 The following table summarizes the components of the net transfers to BD as follows: Year ended September 30, 2022 Cash pooling and general financing activities (1) $ 255.9 Corporate and segment allocations, excluding non-cash stock-based compensation (50.4) Taxes deemed settled with BD (16.2) Other Separation related adjustments, net (11.4) Net transfers to BD as reflected in the Consolidated Statements of Cash Flows 177.9 Share-based compensation expense (8.5) Pension expense (3.6) Net consideration paid to BD in connection with the Separation 1,266.0 Related party senior secured notes 197.0 Other transfers to (from) BD, net 84.1 Net transfers to BD $ 1,712.9 (1)

Segment, Geographic, and Prod_2

Segment, Geographic, and Product Information (Tables)	12 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Schedule of Revenues by Geographical Region	Revenues by geographic region are as follows: Year ended September 30, 2024 2023 2022 United States $ 607.2 $ 601.4 $ 600.3 International (1) 515.9 519.4 529.2 Total $ 1,123.1 $ 1,120.8 $ 1,129.5 (1)
Schedule of Revenues by Product Family	Revenues by product family are as follows: Year ended September 30, 2024 2023 2022 Pen Needles $ 844.4 $ 829.2 $ 824.6 Syringes 126.2 138.1 156.0 Safety 129.4 126.3 119.6 Other (1) 10.3 14.2 14.3 Contract Manufacturing 12.8 13.0 15.0 Total $ 1,123.1 $ 1,120.8 $ 1,129.5 (1) In 2024, Other includes product sales for swabs and other accessories. In 2024, Other also includes the recognition of incremental Italian payback accruals resulting from two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015 which totaled $4.1 million.

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Expense	Total direct and allocated stock-based compensation expense for the fiscal years ended September 30, 2024, 2023, and 2022 and the respective income tax benefits recognized by the Company in the Consolidated Statements of Income are as follows: 2024 2023 2022 Cost of products sold $ 3.0 $ 2.2 $ 2.3 Selling and administrative expense 21.4 18.1 14.6 Research and development expense 2.2 1.6 1.8 Total Stock-Based Compensation Expense $ 26.6 $ 21.9 $ 18.7 Tax benefit associated with stock-based compensation costs recognized $ 3.2 $ 2.7 $ 2.9 The following table summarizes the Company's total stock-based compensation expense by classification of award: 2024 2023 2022 Equity Awards $ 26.3 $ 21.5 $ 18.7 Liability Awards 0.3 0.4 — Total $ 26.6 $ 21.9 $ 18.7 The following table summarizes the Company's total stock-based compensation expense by award type for the fiscal years ended September 30, 2024, 2023 and 2022, subsequent to the Separation: 2024 2023 2022 Time-Vested Restricted Stock Units (TVUs) $ 19.5 $ 16.2 $ 6.6 Performance-Based Restricted Stock Units (PSUs) 3.2 1.0 — Stock Appreciation Rights (SARs) 3.9 4.7 3.7 Total $ 26.6 $ 21.9 $ 10.3
Schedule of Time-Vested Restricted Stock Units Outstanding	A summary of TVUs outstanding as of September 30, 2024 and changes during the fiscal year then ended is as follows: Stock Units (in thousands) Weighted Average Grant Date Fair Value Nonvested at October 1 1,188.8 $ 29.42 Granted 1,437.3 17.39 Distributed* (553.9) 28.41 Forfeited, canceled or expired (154.2) 21.29 Nonvested at September 30 1,918.0 $ 21.34 Expected to vest at September 30 1,823.1 $ 21.40 *The amounts distributed include shares withheld for taxes that are not formally issued to the market. The weighted average grant date fair value of TVUs granted during the fiscal years 2024, 2023 and 2022 are as follows: 2024 2023 2022 Weighted average grant date fair value of units granted $ 17.39 $ 31.00 $ 31.23 The total fair value of TVUs vested during the fiscal years 2024, 2023 and 2022 was as follows: 2024 2023 2022 Total fair value of units vested $ 15.7 $ 10.9 $ 1.6
Schedule of Performance Based Restricted Stock Units Outstanding	A summary of PSUs outstanding as of September 30, 2024 and changes during the fiscal year then ended is as follows: Stock Units (in thousands) Weighted Average Grant Date Fair Value Nonvested at October 1 57.8 $ 30.24 Forfeited, canceled or expired (1.1) 30.24 Nonvested at September 30 56.7 $ 30.24 Expected to vest at September 30 53.5 $ 30.24 The weighted average grant date fair value of PSUs granted during the fiscal year 2023 is as follows: 2023 Weighted average grant date fair value of units granted $ 30.24
Schedule of SARs Valuation Assumptions	The weighted average fair value of SARs was determined using the following assumptions: 2022 Risk-free interest rate 2.5 % Expected volatility 37.8 % Expected dividend yield 2.9 % Expected life 6.5 Fair value per SAR $ 9.38
Schedule of SAR's Outstanding and Changes	A summary of SARs outstanding as of September 30, 2024 and changes during the fiscal year then ended is as follows: SARs (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Balance at October 1 1,831.7 $ 29.06 Forfeited, canceled or expired (71.3) $ 27.70 Balance at September 30 1,760.4 $ 29.11 6.7 $ — Vested and expected to vest at September 30 1,709.7 $ 29.09 6.7 $ — Exercisable at September 30 838.8 $ 28.03 6.1 $ — A summary of SARs exercised during the fiscal years 2023 and 2022 is as follows: 2023 2022 Total intrinsic value of SARs exercised $ 0.3 $ 0.1 Total fair value of SARs exercised $ 0.6 $ 6.1

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill and Intangible Assets	Goodwill and Other Intangible Assets consisted of: Weighted Average Amortization Period (Years) September 30, 2024 September 30, 2023 Amortized intangible assets Patents – gross 11.4 $ 10.8 $ 10.6 Less: accumulated amortization (5.1) (4.5) Patents – net $ 5.7 $ 6.1 Customer Relationships and Other – gross 4.8 $ 5.2 $ 5.4 Less: accumulated amortization (2.8) (2.4) Customer Relationships and Other – net $ 2.4 $ 3.0 Total amortized intangible assets $ 8.1 $ 9.1 Goodwill 15.6 15.6 Total Goodwill and Other Intangible Assets $ 23.7 $ 24.7

Cloud Computing Arrangements (T

Cloud Computing Arrangements (Tables)	12 Months Ended
	Sep. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Capitalized Computer Software, Net	Capitalized costs to implement cloud computing arrangements and accumulated amortization were as follows: September 30, 2024 September 30, 2023 Short-term portion $ 10.2 $ — Long-term portion 60.6 38.0 Total Capitalized implementation costs $ 70.8 $ 38.0 Less: accumulated amortization (6.3) — Total Capitalized implementation costs, net $ 64.5 $ 38.0

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of Debt Outstanding	The following is a summary of Embecta's total debt outstanding as of September 30, 2024: Term Loan due March 2029 $ 901.3 5.00% Notes due February 2030 500.0 6.75% Notes due February 2030 200.0 Total principal debt issued $ 1,601.3 Less: current debt obligations (9.5) Less: debt issuance costs and discounts (26.5) Long-term debt $ 1,565.3 Certain measures relating to our total debt outstanding as of September 30, 2024 were as follows: Total debt $ 1,574.8 Short-term debt as a percentage of total debt 0.6 % Weighted average cost of total debt 6.8 %
Schedule of Principal Payments Required on Long-Term Debt	The schedule of principal payments required on long-term debt for the next five fiscal years and thereafter is as follows: 2025 $ 9.5 2026 9.5 2027 9.5 2028 9.5 2029 863.3 Thereafter 700.0

Earnings per Share (Tables)

Earnings per Share (Tables)	12 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earnings per Share	The calculation of earnings per basic and diluted common share for the fiscal years ended September 30, 2024, 2023 and 2022 were as follows: ($ in millions and shares in thousands, except per share amounts) 2024 2023 2022 Net Income attributable to Embecta $ 78.3 $ 70.4 $ 223.6 Basic weighted average number of shares outstanding 57,681 57,248 57,024 Stock awards and equity units (share equivalent) 645 510 437 Diluted weighted average shares outstanding 58,326 57,758 57,461 Earnings per common share - Basic $ 1.36 $ 1.23 $ 3.92 Earnings per common share - Diluted $ 1.34 $ 1.22 $ 3.89

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Schedule of Income Before Income Taxes	The components of Income Before Income Taxes for the fiscal years ended September 30 consisted of: 2024 2023 2022 Domestic $ (116.7) $ (100.9) $ (29.1) Foreign 160.9 206.6 285.7 Income before income taxes $ 44.2 $ 105.7 $ 256.6
Schedule of Components of Provision (Benefit) for Income Taxes	The provision (benefit) for income taxes for the fiscal years ended September 30 consisted of: 2024 2023 2022 Current: Federal $ 23.4 $ 2.6 $ 20.4 State 2.0 (0.8) 3.4 Foreign 11.1 19.2 35.7 $ 36.5 $ 21.0 $ 59.5 Deferred: Federal $ (44.1) $ 5.9 $ (31.1) State (4.6) 0.7 (4.6) Foreign (21.9) 7.7 9.2 $ (70.6) $ 14.3 $ (26.5) Income tax provision (benefit) $ (34.1) $ 35.3 $ 33.0 The following were included for the fiscal years ended September 30 as a component of Income tax provision (benefit) in the Consolidated Statements of Income and the Consolidated Balance Sheets. 2024 2023 2022 Interest and penalties expense (benefit) associated with unrecognized tax benefits on the Consolidated Statements of Income $ — $ (1.2) $ (1.5) Interest and penalties associated with unrecognized tax benefits on the Consolidated Balance Sheets 0.1 0.2 1.5
Schedule of Tax Rate Reconciliation	A reconciliation of federal statutory tax rate to the Company's effective income tax rate was as follows: 2024 2023 2022 Federal statutory tax rate 21.0 % 21.0 % 21.0 % State and local income taxes, net of federal tax benefit (6.8) — (0.8) Foreign income tax at rates other than 21% (43.4) (17.3) (7.0) US tax on foreign earnings 2.7 12.5 0.2 Taxes on unremitted foreign earnings (40.6) 11.1 3.2 Tax reserves 14.5 (0.4) (1.8) Valuation allowances 41.9 14.0 — Tax credits (7.5) (1.5) (0.7) Tax law changes (65.0) — — Nontaxable items (12.2) (8.6) (1.1) Nondeductible expenses 16.5 2.5 — Other, net 1.8 0.1 (0.1) Effective income tax rate (77.1) % 33.4 % 12.9 %
Schedule of Deferred Income Taxes	Deferred income taxes at September 30 consisted of: 2024 2023 Deferred tax assets: Compensation and benefits $ 13.2 $ 9.7 Accruals and reserves 23.8 9.1 Intangibles 46.4 24.6 Property, plant and equipment 10.7 11.7 Capitalized research and development expenses 25.9 16.6 Leases 11.6 12.9 Deferred income 13.3 — Interest expense carryforwards 27.8 16.4 Tax loss and credit carryforwards 12.5 6.6 Other 5.9 2.1 Gross deferred tax assets before valuation allowance $ 191.1 $ 109.7 Valuation allowance $ (50.2) $ (31.6) Total deferred tax assets $ 140.9 $ 78.1 Deferred tax liabilities: Taxes on unremitted foreign earnings $ (1.9) $ (20.5) Right of use asset (12.1) (12.8) Capitalized cloud computing costs (10.7) — Total deferred tax liabilities $ (24.7) (33.3) Net deferred tax assets (liabilities) (i) $ 116.2 $ 44.8 i. Net deferred tax assets are included in Deferred Income Taxes and Other Assets and net deferred tax liabilities are included in Deferred Income Taxes and Other Liabilities in the Consolidated Balance Sheets.
Schedule of Unrecognized Tax Benefits	The table below summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled. 2024 2023 2022 Balance at October 1 $ 9.4 $ 5.7 $ 16.0 Increase due to current year tax positions 8.9 5.0 1.0 Increase due to prior year tax positions 2.1 3.7 — Decrease due to prior year tax positions (6.9) (0.3) (6.7) Decrease due to settlements with tax authorities — — — Decrease due to lapse of statute of limitations — (4.7) (4.6) Balance at September 30 $ 13.5 $ 9.4 $ 5.7 Unrecognized tax benefits including interest and penalties that would affect the effective tax rate if recognized $ 13.6 $ 7.2 $ 7.2

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	12 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Cash and Cash Equivalents	The following reconciles Cash and equivalents and Restricted cash reported within the Consolidated Balance Sheets as of September 30, 2024 and September 30, 2023, to the total amounts shown in the Consolidated Statements of Cash Flows: September 30, 2024 September 30, 2023 Cash and equivalents $ 267.5 $ 326.3 Restricted cash 6.7 0.2 Cash and equivalents and restricted cash $ 274.2 $ 326.5
Schedule of Restrictions on Cash	The following reconciles Cash and equivalents and Restricted cash reported within the Consolidated Balance Sheets as of September 30, 2024 and September 30, 2023, to the total amounts shown in the Consolidated Statements of Cash Flows: September 30, 2024 September 30, 2023 Cash and equivalents $ 267.5 $ 326.3 Restricted cash 6.7 0.2 Cash and equivalents and restricted cash $ 274.2 $ 326.5
Schedule of Notional Amounts of Derivative Instruments	The notional amounts of the Company’s foreign currency-related derivative instruments were as follows: Hedge Designation September 30, 2024 September 30, 2023 Foreign exchange contracts (a) Undesignated $ 4.5 $ 6.7 a. Represent hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and receivables. Gains and losses on these instruments are recognized immediately in Other income (expense), net . These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Gains and losses recognized to date on these instruments were not material to the Company's Consolidated Financial Statements.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, Plant and Equipment, Net consisted of: As of September 30, 2024 As of September 30, 2023 Land $ 3.1 $ 2.3 Buildings 121.7 124.5 Machinery, equipment and fixtures 607.3 567.2 Leasehold improvements 11.9 9.1 Construction in progress 35.1 44.8 $ 779.1 $ 747.9 Less: accumulated depreciation (488.7) (447.7) Total Property, Plant and Equipment, Net $ 290.4 $ 300.2

Leases (Tables)

Leases (Tables)	12 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Schedule of Balance Sheet Information	The Company's leases are included in its Consolidated Balance Sheets as follows: As of September 30, 2024 As of September 30, 2023 Finance Lease Property, Plant, and Equipment, Net $ 30.8 $ 33.1 Total Finance Lease Assets $ 30.8 $ 33.1 Current finance lease liabilities $ 3.4 $ 3.6 Non Current Finance Lease Liabilities 30.2 31.5 Total Finance Lease Liabilities $ 33.6 $ 35.1 Weighted-average remaining lease term (years) 12.5 13.5 Weighted-average discount rate 6.8 % 6.8 % Operating Leases Deferred Income Taxes and Other Assets $ 22.6 $ 23.0 Total Operating Lease Assets $ 22.6 $ 23.0 Accrued expenses $ 6.0 $ 5.9 Deferred Income Taxes and Other Liabilities 11.9 15.4 Total Operating Lease Liabilities $ 17.9 $ 21.3 Weighted-average remaining lease term (years) 6.3 7.3 Weighted-average discount rate 6.5 % 6.9 %
Schedule of Supplemental Cash Flow Information	Lease costs incurred are as follows: (in millions) Classification 2024 2023 Operating lease expense Selling and administrative and Research and Development expense $ 7.5 $ 4.5 Finance lease cost: Depreciation of lease assets Cost of products sold 2.5 2.4 Interest on lease liabilities Interest expense, net 2.4 2.4 Total lease cost $ 12.4 $ 9.3 Supplemental cash flow information related to leases was as follows as of September 30, 2024, 2023 and 2022: September 30, 2024 September 30, 2023 September 30, 2022 Right of use assets obtained in exchange for lease liabilities Finance Lease $ — $ — $ 36.7 Operating Leases 3.0 19.0 2.8 September 30, 2024 September 30, 2023 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from Operating Leases $ 6.4 $ 2.9 Financing cash flows from Finance Lease 1.3 1.2 Operating cash flows from Finance Lease 2.4 2.4
Schedule of Maturities of Finance Lease Liabilities	Maturities of the Company's finance and operating lease liabilities as of September 30, 2024 by fiscal year are as follows: Finance Leases Operating Leases Total 2025 3.7 6.2 9.9 2026 3.7 3.4 7.1 2027 3.8 1.8 5.6 2028 3.9 1.8 5.7 2029 3.9 1.7 5.6 Thereafter 32.3 7.3 39.6 Total lease payments $ 51.3 $ 22.2 $ 73.5 Less: amount representing interest 17.7 4.3 22.0 Present value of lease liabilities $ 33.6 $ 17.9 $ 51.5
Schedule of Maturities of Operating Lease Liabilities	Maturities of the Company's finance and operating lease liabilities as of September 30, 2024 by fiscal year are as follows: Finance Leases Operating Leases Total 2025 3.7 6.2 9.9 2026 3.7 3.4 7.1 2027 3.8 1.8 5.6 2028 3.9 1.8 5.7 2029 3.9 1.7 5.6 Thereafter 32.3 7.3 39.6 Total lease payments $ 51.3 $ 22.2 $ 73.5 Less: amount representing interest 17.7 4.3 22.0 Present value of lease liabilities $ 33.6 $ 17.9 $ 51.5

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	12 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Allowance for Doubtful Accounts and Cash Discounts	The amounts recognized in fiscal years 2024, 2023 and 2022 relating to allowances for doubtful accounts and cash discounts, which are netted against trade receivables, are provided in the following table: Allowance for Doubtful Accounts Allowance for Cash Discounts Total Balance at September 30, 2021 (3.1) (3.1) (6.2) Additions charged to costs and expenses (0.3) (18.1) (18.4) Deductions and other 2.1 (b) 21.1 23.2 Balance at September 30, 2022 (1.3) (0.1) (1.4) Additions charged to costs and expenses (0.2) (18.7) (18.9) Deductions and other 0.5 (a) 18.8 19.3 Balance at September 30, 2023 (1.0) — (1.0) Additions charged to costs and expenses (2.2) (17.5) (19.7) Deductions and other 0.4 (a) (3.6) (3.2) Balance at September 30, 2024 (2.8) (21.1) (23.9) (a) Accounts written off (b) Amounts factored to BD
Schedule of Long-Lived Assets by Geographic Area	Long-lived assets, which include Property, Plant and Equipment, net , and Goodwill and Other Intangibles, net, by geographic area where located at September 30, 2024 and 2023 is as follows: 2024 2023 United States $ 105.0 $ 109.2 Europe, Middle East, and Africa 170.8 176.9 Asia 37.2 38.4 Other 1.1 0.4 $ 314.1 $ 324.9

Background (Details)

Background (Details)	Apr. 01, 2022 $ / shares	Sep. 30, 2024 $ / shares	Sep. 30, 2023 $ / shares
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Common stock, distribution ratio	0.2
Becton, Dickinson and Company
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Common stock, par value (in dollars per share)	$ 1

Summary of Accounting Policie_2

Summary of Accounting Policies (Details)		12 Months Ended
	Jul. 01, 2024 USD ($)	Sep. 30, 2024 USD ($) segment reporting_unit	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Property, Plant and Equipment [Line Items]
Depreciation		$ 34,900,000	$ 31,500,000	$ 31,000,000
Advertising costs		$ 9,000,000	15,500,000	11,600,000
Number of reporting units | reporting_unit		1
Goodwill impairments	$ 0	$ 0	0	0
Accumulated impairment loss		0	0	0
Transactional foreign exchange losses		4,400,000
Selling and administrative expense		$ 365,100,000	341,300,000	294,800,000
Number of operating segments | segment		1
Number of reportable segments | segment		1
Cash paid for interest, net of interest capitalized		$ 117,700,000	111,000,000	38,900,000
Cash paid for income taxes, net of refunds		29,100,000	30,400,000	15,600,000
Shipping and Handling
Property, Plant and Equipment [Line Items]
Selling and administrative expense		$ 41,300,000	36,900,000	27,400,000
Patents – net
Property, Plant and Equipment [Line Items]
Intangible assets useful life		20 years
Property, Plant and Equipment, Net
Property, Plant and Equipment [Line Items]
Interest expense capitalized		$ 3,700,000	4,600,000	$ 5,200,000
Deferred Income Taxes and Other Assets
Property, Plant and Equipment [Line Items]
Interest expense capitalized		$ 0	$ 900,000
Minimum | Customer Relationships
Property, Plant and Equipment [Line Items]
Intangible assets useful life		10 years
Minimum | Other Intangible Assets
Property, Plant and Equipment [Line Items]
Intangible assets useful life		1 year
Minimum | Buildings
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life		20 years
Minimum | Machinery and Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life		4 years
Minimum | Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life		1 year
Maximum | Customer Relationships
Property, Plant and Equipment [Line Items]
Intangible assets useful life		15 years
Maximum | Other Intangible Assets
Property, Plant and Equipment [Line Items]
Intangible assets useful life		40 years
Maximum | Buildings
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life		45 years
Maximum | Machinery and Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life		13 years
Maximum | Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life		20 years

Third Party Arrangements and _3

Third Party Arrangements and Related Party Disclosures - Additional Information (Details) - USD ($)	Jan. 01, 2024	Apr. 01, 2022	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2022
Related Party Transaction [Line Items]
Amounts due from Becton, Dickinson and Company			$ 53,800,000	$ 142,400,000
Amounts due to Becton, Dickinson and Company			42,500,000	73,100,000
Prepaid expenses and other			68,500,000	111,400,000
Accrued expenses			134,200,000	$ 118,100,000
6.75% Senior Secured Notes due 2030 | Senior Notes | Parent
Related Party Transaction [Line Items]
Face amount		$ 200,000,000			$ 200,000,000
Becton, Dickinson and Company
Related Party Transaction [Line Items]
Cannula Supply Agreement, minimum notice period to terminate agreement		36 months
Cannula Supply Agreement, minimum period from distribution date to terminate agreement		10 years
Becton, Dickinson and Company
Related Party Transaction [Line Items]
Trade Receivables Factoring Agreement Service fee as a percentage of annual revenue		0.10%
Distribution Agreement, maximum term for distributor appointed		2 years
Cannula Supply Agreement, minimum notice period to terminate agreement		36 months
Cannula Supply Agreement, minimum period from distribution date to terminate agreement		5 years
Cannula Supply Agreement, termination related to yearly forecasted purchase minimum, wind-down period		36 months
Logistics Services Agreement, maximum term		2 years
Logistics Services Agreement, administrative fee as a percentage of net revenue	1.25%	1%
Amounts due to Becton, Dickinson and Company			42,500,000
Prepaid expenses and other			7,000,000
Accrued expenses			6,300,000
Becton, Dickinson and Company | Amounts due from Becton, Dickinson and Company
Related Party Transaction [Line Items]
Amounts due from Becton, Dickinson and Company			53,800,000
Becton, Dickinson and Company | Trade receivables, net
Related Party Transaction [Line Items]
Amounts due from Becton, Dickinson and Company			$ 10,900,000
Becton, Dickinson and Company | Minimum
Related Party Transaction [Line Items]
Distribution Agreement, fee paid as a percentage of net revenue for each territory		1.50%
Becton, Dickinson and Company | Maximum
Related Party Transaction [Line Items]
Distribution Agreement, fee paid as a percentage of net revenue for each territory		2%

Third Party Arrangements and _4

Third Party Arrangements and Related Party Disclosures - Allocation of General Corporate Expenses (Details) $ in Millions	12 Months Ended
	Sep. 30, 2022 USD ($)
Related Party Transaction [Line Items]
Total General Corporate Expenses	$ 53.1
Cost of products sold
Related Party Transaction [Line Items]
Total General Corporate Expenses	2.3
Selling and administrative expense
Related Party Transaction [Line Items]
Total General Corporate Expenses	47.9
Research and development expense
Related Party Transaction [Line Items]
Total General Corporate Expenses	3.5
Other (income) expense, net
Related Party Transaction [Line Items]
Total General Corporate Expenses	$ (0.6)

Third Party Arrangements and _5

Third Party Arrangements and Related Party Disclosures - Purchases from Parent (Details) $ in Millions	12 Months Ended
	Sep. 30, 2022 USD ($)
Parent
Related Party Transaction [Line Items]
Purchases from BD	$ 28

Third Party Arrangements and _6

Third Party Arrangements and Related Party Disclosures - Net Transfers to Parent (Details) $ in Millions	12 Months Ended
	Sep. 30, 2022 USD ($)
Third Party and Related Party Transactions [Abstract]
Cash pooling and general financing activities	$ 255.9
Corporate and segment allocations, excluding non-cash stock-based compensation	(50.4)
Taxes deemed settled with BD	(16.2)
Other Separation related adjustments, net	(11.4)
Net transfers to BD as reflected in the Consolidated Statements of Cash Flows	177.9
Share-based compensation expense	(8.5)
Pension expense	(3.6)
Net consideration paid to BD in connection with the Separation	1,266
Related party senior secured notes	197
Other transfers to (from) BD, net	84.1
Net transfers to BD	$ 1,712.9

Collaboration Agreement (Detail

Collaboration Agreement (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense	$ 78.8	$ 85.2	$ 66.9
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense		$ 2.5

Other Operating Expenses (Detai

Other Operating Expenses (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Other Income and Expenses [Abstract]
Separation and stand-up costs	$ 110,800,000	$ 92,700,000	$ 44,700,000
Amortization of cloud computing costs	6,300,000	0	0
Severance costs	$ 7,400,000	$ 5,600,000	$ 0

Revenues (Details)

Revenues (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Customer rebate liability	$ 149.6	$ 36.4
Rebates recorded	525.9	411.1	$ 336.4
Contract asset	$ 1.2	$ 1.2

Segment, Geographic, and Prod_3

Segment, Geographic, and Product Information - Schedule of Revenues by Geographical Region (Details) $ in Millions	12 Months Ended
	Sep. 30, 2024 USD ($) segment	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Segment Reporting [Abstract]
Number of operating segments | segment	1
Segment Reporting Information [Line Items]
Revenues	$ 1,123.1	$ 1,120.8	$ 1,129.5
United States
Segment Reporting Information [Line Items]
Revenues	607.2	601.4	600.3
International
Segment Reporting Information [Line Items]
Revenues	$ 515.9	$ 519.4	$ 529.2

Segment, Geographic, and Prod_4

Segment, Geographic, and Product Information - Schedule of Revenues by Product Family (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Revenues	$ 1,123.1	$ 1,120.8	$ 1,129.5
Pen Needles
Segment Reporting Information [Line Items]
Revenues	844.4	829.2	824.6
Syringes
Segment Reporting Information [Line Items]
Revenues	126.2	138.1	156
Safety
Segment Reporting Information [Line Items]
Revenues	129.4	126.3	119.6
Other
Segment Reporting Information [Line Items]
Revenues	10.3	14.2	14.3
Other | Italy
Segment Reporting Information [Line Items]
Revenues	4.1
Contract Manufacturing
Segment Reporting Information [Line Items]
Revenues	$ 12.8	$ 13	$ 15

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ in Millions		12 Months Ended
	Apr. 01, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unrecognized compensation expense		$ 29.5
Weighted average remaining term of awards		1 year 8 months 12 days
SARs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Weighted average remaining term of awards		6 years 8 months 12 days
Time Vested Restricted Stock Units
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Vesting period		3 years
Awards granted (in shares)		1,437,311
Weighted average remaining term of awards		1 year 7 months 6 days
Performance Stock Units (PSUs) | Executive Officers and Employees
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Vesting period		3 years
Awards granted (in shares)		553,235
Performance Based Restricted Stock Units
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Weighted average remaining term of awards		1 year 2 months 12 days
2022 Employee and Director Equity Based Compensation Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total incremental cost to be recognized	$ 6.1
Incremental cost recognized		$ 1.2	$ 1.8	$ 2.3
Unrecognized compensation expense		$ 0.8
Number of shares authorized (in shares)	10,189,000
Authorized for future grant ( in shares )		2,700,000
2022 Employee and Director Equity Based Compensation Plan | SARs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award term	10 years
2022 Employee and Director Equity Based Compensation Plan | SARs | Minimum
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Vesting period	3 years
2022 Employee and Director Equity Based Compensation Plan | SARs | Maximum
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Vesting period	4 years

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-Based Compensation Expense	$ 10.3	$ 26.6	$ 21.9	$ 18.7
Tax benefit associated with stock-based compensation costs recognized		3.2	2.7	2.9
Equity Awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-Based Compensation Expense		26.3	21.5	18.7
Liability Awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-Based Compensation Expense		0.3	0.4	0
Time-Vested Restricted Stock Units (TVUs)
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-Based Compensation Expense	6.6	19.5	16.2
Performance-Based Restricted Stock Units (PSUs)
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-Based Compensation Expense	0	3.2	1
Stock Appreciation Rights (SARs)
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-Based Compensation Expense	$ 3.7	3.9	4.7
Cost of products sold
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-Based Compensation Expense		3	2.2	2.3
Selling and administrative expense
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-Based Compensation Expense		21.4	18.1	14.6
Research and development expense
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-Based Compensation Expense		$ 2.2	$ 1.6	$ 1.8

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units Activity (Details) - $ / shares	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Time Vested Restricted Stock Units
Stock Units (in thousands)
Nonvested, Beginning Balance (in shares)	1,188,800
Granted (in shares)	1,437,311
Distributed (in shares)	(553,900)
Forfeited, canceled or expired (in shares)	(154,200)
Nonvested, Ending Balance (in shares)	1,918,000	1,188,800
Expected to vest (in shares)	1,823,100
Weighted Average Grant Date Fair Value
Nonvested, Beginning Balance (in dollars per share)	$ 29.42
Granted (in dollars per share)	17.39	$ 31	$ 31.23
Distributed (in dollars per share)	28.41
Forfeited, canceled or expired (in dollars per share)	21.29
Nonvested, Ending Balance (in dollars per share)	21.34	$ 29.42
Expected to vest (in dollars per share)	$ 21.40
Performance Based Restricted Stock Units
Stock Units (in thousands)
Nonvested, Beginning Balance (in shares)	57,800
Forfeited, canceled or expired (in shares)	(1,100)
Nonvested, Ending Balance (in shares)	56,700	57,800
Expected to vest (in shares)	53,500
Weighted Average Grant Date Fair Value
Nonvested, Beginning Balance (in dollars per share)	$ 30.24
Granted (in dollars per share)		$ 30.24
Forfeited, canceled or expired (in dollars per share)	30.24
Nonvested, Ending Balance (in dollars per share)	30.24	$ 30.24
Expected to vest (in dollars per share)	$ 30.24

Stock-Based Compensation - Weig

Stock-Based Compensation - Weighted Average Grant Date Fair Value of Performance-Based and Time-Vested Restricted Stock Units Granted (Details) - $ / shares	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Time Vested Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of units granted	$ 17.39	$ 31	$ 31.23
Performance Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of units granted		$ 30.24

Stock-Based Compensation - Tota

Stock-Based Compensation - Total Fair Value of Time Vested Stock Units Vested (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Time Vested Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of units vested	$ 15.7	$ 10.9	$ 1.6

Stock-Based Compensation - SARs

Stock-Based Compensation - SARs Valuation Assumptions (Details) - SARs	12 Months Ended
	Sep. 30, 2022 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.50%
Expected volatility	37.80%
Expected dividend yield	2.90%
Expected life	6 years 6 months
Fair value per SAR (in dollars per share)	$ 9.38

Stock-Based Compensation - SA_2

Stock-Based Compensation - SARs Outstanding and the Changes (Details) $ / shares in Units, $ in Millions	12 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Additional Disclosures
Outstanding, Weighted Average Remaining Contractual Term	1 year 8 months 12 days
SARs
SARs (in thousands)
Outstanding, Beginning Balance (in shares) | shares	1,831,700
Forfeited, canceled or expired (in shares) | shares	(71,300)
Outstanding, Ending Balance (in shares) | shares	1,760,400
Vested and expected to vest (in shares) | shares	1,709,700
Exercisable (in shares) | shares	838,800
Weighted Average Exercise Price
Outstanding, Beginning Balance (in dollars per share) | $ / shares	$ 29.06
Forfeited, canceled or expired (in dollars per share) | $ / shares	27.70
Outstanding, Ending Balance (in dollars per share) | $ / shares	29.11
Vested and expected to vest, Weighted Average Exercise Price (in dollars per share) | $ / shares	29.09
Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 28.03
Additional Disclosures
Outstanding, Weighted Average Remaining Contractual Term	6 years 8 months 12 days
Vested and expected to vest, Weighted Average Remaining Contractual Term	6 years 8 months 12 days
Exercisable, Weighted Average Remaining Contractual Term	6 years 1 month 6 days
Outstanding, Aggregate Intrinsic Value | $	$ 0
Vested and expected to vest, Aggregate Intrinsic Value | $	0
Exercisable, Aggregate Intrinsic Value | $	$ 0

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of SARs Exercised (Details) - SARs - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total intrinsic value of SARs exercised	$ 0.3	$ 0.1
Total fair value of SARs exercised	$ 0.6	$ 6.1

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Schedule of Goodwill and Intangible Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Total amortized intangible assets	$ 8.1	$ 9.1
Goodwill	15.6	15.6
Total Goodwill and Other Intangible Assets	$ 23.7	24.7
Patents – net
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	11 years 4 months 24 days
Amortized intangible assets - gross	$ 10.8	10.6
Amortized intangible assets - Less: accumulated amortization	(5.1)	(4.5)
Total amortized intangible assets	$ 5.7	6.1
Customer Relationships and Other – net
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	4 years 9 months 18 days
Amortized intangible assets - gross	$ 5.2	5.4
Amortized intangible assets - Less: accumulated amortization	(2.8)	(2.4)
Total amortized intangible assets	$ 2.4	$ 3

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible asset amortization expense	$ 1.1	$ 1.2	$ 0.7
Estimated intangible asset amortization expense for 2025	1.1
Estimated intangible asset amortization expense for 2026	1.1
Estimated intangible asset amortization expense for 2027	1.1
Estimated intangible asset amortization expense for 2028	1.1
Estimated intangible asset amortization expense for 2029	1.1
Estimated intangible asset amortization expense for subsequent years thereafter	$ 2.8

Cloud Computing Arrangements -

Cloud Computing Arrangements - Schedule of Capitalized Computer Software, Net (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Short-term portion	$ 10.2	$ 0
Long-term portion	60.6	38
Total Capitalized implementation costs	70.8	38
Less: accumulated amortization	(6.3)	0
Total Capitalized implementation costs, net	$ 64.5	$ 38

Cloud Computing Arrangements _2

Cloud Computing Arrangements - Additional Information (Details) - USD ($)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Amortization of cloud computing costs	$ 6,300,000	$ 0	$ 0
Minimum
Cloud computing arrangement assets in-service useful lives	2 years
Maximum
Cloud computing arrangement assets in-service useful lives	8 years

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Details) - USD ($)		1 Months Ended	12 Months Ended
	Mar. 31, 2022	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Apr. 01, 2022	Feb. 10, 2022
Debt Instrument [Line Items]
Cash paid for interest, net of interest capitalized			$ 117,700,000	$ 111,000,000	$ 38,900,000
Level 2 | Fair Value
Debt Instrument [Line Items]
Long-term debt		$ 1,527,300,000	1,527,300,000
Level 2 | Reported Value Measurement
Debt Instrument [Line Items]
Long-term debt		$ 1,574,800,000	$ 1,574,800,000
5.00% Senior Secured Notes due 2030 | Senior Notes
Debt Instrument [Line Items]
Stated interest rate		5%	5%				5%
Face amount							$ 500,000,000
6.75% Senior Secured Notes due 2030 | Senior Notes
Debt Instrument [Line Items]
Stated interest rate		6.75%	6.75%			6.75%
6.75% Senior Secured Notes due 2030 | Senior Notes | Parent
Debt Instrument [Line Items]
Stated interest rate	6.75%
Face amount	$ 200,000,000					$ 200,000,000
Discount	3,000,000
Term Loan due March 2029 | Secured Debt
Debt Instrument [Line Items]
Face amount	$ 950,000,000
Term	7 years
Basis spread on variable rate	3%
Variable rate floor	0.50%
Discount percentage	0.50%
Quarterly payment as a percentage of principal	0.25%
Repayments of Secured Debt		$ 25,000,000
Revolving Credit Facility | Secured Debt | Revolving Credit Facility
Debt Instrument [Line Items]
Term	5 years
Maximum borrowing capacity	$ 500,000,000
Commitment fee percentage	0.25%
Amount drawn		$ 0	$ 0

Long-Term Debt - Debt Outstandi

Long-Term Debt - Debt Outstanding (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023	Apr. 01, 2022	Feb. 10, 2022
Debt Instrument [Line Items]
Total principal debt issued	$ 1,601.3
Less: current debt obligations	(9.5)	$ (9.5)
Less: debt issuance costs and discounts	(26.5)
Long-term debt	1,565.3	$ 1,593.9
Secured Debt | Term Loan due March 2029
Debt Instrument [Line Items]
Total principal debt issued	$ 901.3
Senior Notes | 5.00% Notes due February 2030
Debt Instrument [Line Items]
Stated interest rate	5%			5%
Total principal debt issued	$ 500
Senior Notes | 6.75% Notes due February 2030
Debt Instrument [Line Items]
Stated interest rate	6.75%		6.75%
Total principal debt issued	$ 200

Long-Term Debt - Principal Paym

Long-Term Debt - Principal Payments Required on Long-Term Debt (Details) $ in Millions	Sep. 30, 2024 USD ($)
Debt Disclosure [Abstract]
2025	$ 9.5
2026	9.5
2027	9.5
2028	9.5
2029	863.3
Thereafter	$ 700

Long-Term Debt - Total Debt Out

Long-Term Debt - Total Debt Outstanding (Details) $ in Millions	Sep. 30, 2024 USD ($)
Debt Disclosure [Abstract]
Total debt	$ 1,574.8
Short-term debt as a percentage of total debt	0.60%
Weighted average cost of total debt	6.80%

Earnings per Share - Computatio

Earnings per Share - Computation of Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Income attributable to Embecta	$ 78.3	$ 70.4	$ 223.6
Basic weighted average number of shares outstanding (in shares)	57,681	57,248	57,024
Stock awards and equity units (share equivalent) (in shares)	645	510	437
Diluted weighted average shares outstanding (in shares)	58,326	57,758	57,461
Earnings per common share - Basic (in dollars per share)	$ 1.36	$ 1.23	$ 3.92
Earnings per common share - Diluted (in dollars per share)	$ 1.34	$ 1.22	$ 3.89

Earnings per Share - Additional

Earnings per Share - Additional Information (Details) - shares shares in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	2.8	1.8	1.8

Income Taxes - Income Before In

Income Taxes - Income Before Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Domestic	$ (116.7)	$ (100.9)	$ (29.1)
Foreign	160.9	206.6	285.7
Income Before Income Taxes	$ 44.2	$ 105.7	$ 256.6

Income Taxes - Provision (Benef

Income Taxes - Provision (Benefit) for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Current:
Federal	$ 23.4	$ 2.6	$ 20.4
State	2	(0.8)	3.4
Foreign	11.1	19.2	35.7
Current total	36.5	21	59.5
Deferred:
Federal	(44.1)	5.9	(31.1)
State	(4.6)	0.7	(4.6)
Foreign	(21.9)	7.7	9.2
Deferred total	(70.6)	14.3	(26.5)
Income tax provision (benefit)	$ (34.1)	$ 35.3	$ 33

Income Taxes - Tax Rate Reconci

Income Taxes - Tax Rate Reconciliation (Details)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Federal statutory tax rate	21%	21%	21%
State and local income taxes, net of federal tax benefit	(6.80%)	0%	(0.80%)
Foreign income tax at rates other than 21%	(43.40%)	(17.30%)	(7.00%)
US tax on foreign earnings	2.70%	12.50%	0.20%
Taxes on unremitted foreign earnings	(40.60%)	11.10%	3.20%
Tax reserves	14.50%	(0.40%)	(1.80%)
Valuation allowances	41.90%	14%	0%
Tax credits	(7.50%)	(1.50%)	(0.70%)
Tax law changes	(65.00%)	0%	0%
Nontaxable items	(12.20%)	(8.60%)	(1.10%)
Nondeductible expenses	16.50%	2.50%	0%
Other, net	1.80%	0.10%	(0.10%)
Effective income tax rate	(77.10%)	33.40%	12.90%

Income Taxes - Deferred Income

Income Taxes - Deferred Income Taxes (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Deferred tax assets:
Compensation and benefits	$ 13.2	$ 9.7
Accruals and reserves	23.8	9.1
Intangibles	46.4	24.6
Property, plant and equipment	10.7	11.7
Capitalized research and development expenses	25.9	16.6
Leases	11.6	12.9
Deferred income	13.3	0
Interest expense carryforwards	27.8	16.4
Tax loss and credit carryforwards	12.5	6.6
Other	5.9	2.1
Gross deferred tax assets before valuation allowance	191.1	109.7
Valuation allowance	(50.2)	(31.6)
Total deferred tax assets	140.9	78.1
Deferred tax liabilities:
Taxes on unremitted foreign earnings	(1.9)	(20.5)
Right of use asset	(12.1)	(12.8)
Capitalized cloud computing costs	(10.7)	0
Total deferred tax liabilities	(24.7)	(33.3)
Net deferred tax assets (liabilities)	$ 116.2	$ 44.8

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Tax Credit Carryforward [Line Items]
Tax benefits of reversal of taxes on unremitted foreign earnings	$ 16.8
Tax benefit	28.7
Valuation allowances	50.2	$ 31.6
Tax impact related to tax holidays	$ 0.7
Impact of tax holidays on diluted earnings per share (in dollars per share)	$ 0.01
Operating loss carryforwards	$ 3.1
Net operating loss carryforwards, not subject to expiration	0.3
State Income Tax Credit Carryforwards
Tax Credit Carryforward [Line Items]
Tax credit carryforward	3.1
Foreign Tax Jurisdiction
Tax Credit Carryforward [Line Items]
Tax credit carryforward	$ 6.3

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance	$ 9.4	$ 5.7	$ 16
Increase due to current year tax positions	8.9	5	1
Increase due to prior year tax positions	2.1	3.7	0
Decrease due to prior year tax positions	(6.9)	(0.3)	(6.7)
Decrease due to settlements with tax authorities	0	0	0
Decrease due to lapse of statute of limitations	0	(4.7)	(4.6)
Ending balance	13.5	9.4	5.7
Unrecognized tax benefits including interest and penalties that would affect the effective tax rate if recognized	$ 13.6	$ 7.2	$ 7.2

Income Taxes - Interest and Pen

Income Taxes - Interest and Penalties (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Interest and penalties expense (benefit) associated with unrecognized tax benefits on the Consolidated Statements of Income	$ 0	$ (1.2)	$ (1.5)
Interest and penalties associated with unrecognized tax benefits on the Consolidated Balance Sheets	$ 0.1	$ 0.2	$ 1.5

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurements - Cash and Cash Equivalents (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Cash and equivalents	$ 267.5	$ 326.3
Restricted cash	6.7	0.2
Cash and equivalents and restricted cash	$ 274.2	$ 326.5	$ 330.9	$ 0

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest income		$ 12	$ 9.4	$ 0
Impairment charges		0	2.5	$ 58.9
Trade receivables	$ 193	$ 193	$ 16.7
Customer Concentration Risk | Revenues | Three Customers in Aggregate
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Concentration risk percentage		41.30%	40.20%	40.10%
Customer Concentration Risk | Accounts Receivable | One Customer
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Concentration risk percentage	11.10%

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measurements - Notional Amounts of Derivative Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Foreign exchange contracts | Undesignated
Derivative [Line Items]
Notional amount	$ 4.5	$ 6.7

Property, Plant and Equipment -

Property, Plant and Equipment - Components of Property, Plant and Equipment, Net (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 779.1	$ 747.9
Less: accumulated depreciation	(488.7)	(447.7)
Total Property, Plant and Equipment, Net	290.4	300.2
Land
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	3.1	2.3
Buildings
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	121.7	124.5
Machinery, equipment and fixtures
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	607.3	567.2
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	11.9	9.1
Construction in progress
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 35.1	$ 44.8

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Impairment charges	$ 0	$ 2.5	$ 58.9

Leases - Additional Information

Leases - Additional Information (Details) ft² in Thousands, $ in Millions	12 Months Ended
	Sep. 30, 2024 USD ($) ft²	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Mar. 31, 2023
Lessee, Lease, Description [Line Items]
Area of space leased (in square feet) | ft²	278
Term of finance lease	10 years
Finance lease renewal term	5 years
Term of operating lease				10 years
Finance lease cost			$ 0
Operating lease expense	$ 7.5	$ 4.5	$ 0
Building Lease, Six Year Extension Option
Lessee, Lease, Description [Line Items]
Operating lease renewal term	6 years
Building Lease, Four Year Extension Option
Lessee, Lease, Description [Line Items]
Operating lease renewal term	4 years

Leases - Balance Sheet Informat

Leases - Balance Sheet Information (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Finance Lease
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, Plant and Equipment, Net	Property, Plant and Equipment, Net
Total Finance Lease Assets	$ 30.8	$ 33.1
Current finance lease liabilities	3.4	3.6
Non Current Finance Lease Liabilities	30.2	31.5
Total Finance Lease Liabilities	$ 33.6	$ 35.1
Weighted-average remaining lease term (years)	12 years 6 months	13 years 6 months
Weighted-average discount rate	6.80%	6.80%
Operating Leases
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Deferred Income Taxes and Other Assets	Deferred Income Taxes and Other Assets
Total Operating Lease Assets	$ 22.6	$ 23
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued expenses	Accrued expenses
Accrued expenses	$ 6	$ 5.9
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Deferred Income Taxes and Other Liabilities	Deferred Income Taxes and Other Liabilities
Deferred Income Taxes and Other Liabilities	$ 11.9	$ 15.4
Total Operating Lease Liabilities	$ 17.9	$ 21.3
Weighted-average remaining lease term (years)	6 years 3 months 18 days	7 years 3 months 18 days
Weighted-average discount rate	6.50%	6.90%

Leases - Lease Costs (Details)

Leases - Lease Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Operating lease expense	$ 7.5	$ 4.5	$ 0
Finance lease cost: Depreciation of lease assets	2.5	2.4
Finance lease cost: Interest on lease liabilities	2.4	2.4
Total lease cost	$ 12.4	$ 9.3

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Right of use assets obtained in exchange for lease liabilities
Finance Lease	$ 0	$ 0	$ 36.7
Operating Leases	3	19	2.8
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from Operating Leases	6.4	2.9
Financing cash flows from Finance Lease	1.3	1.2	$ 1.8
Operating cash flows from Finance Lease	$ 2.4	$ 2.4

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Finance Leases
2025	$ 3.7
2026	3.7
2027	3.8
2028	3.9
2029	3.9
Thereafter	32.3
Total lease payments	51.3
Less: amount representing interest	17.7
Present value of lease liabilities	33.6	$ 35.1
Operating Leases
2025	6.2
2026	3.4
2027	1.8
2028	1.8
2029	1.7
Thereafter	7.3
Total lease payments	22.2
Less: amount representing interest	4.3
Present value of lease liabilities	17.9	$ 21.3
Total
2025	9.9
2026	7.1
2027	5.6
2028	5.7
2029	5.6
Thereafter	39.6
Total lease payments	73.5
Less: amount representing interest	22
Present value of lease liabilities	$ 51.5

Benefit Plans (Details)

Benefit Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Defined Benefit Plan Disclosure [Line Items]
Benefit plan expense			$ 3.6
Total employer contributions	$ 15.1	$ 14.1	$ 8.9
Maximum deferral percentage of base salary under deferred compensation plan	75%
Maximum deferral percentage of bonus and other eligible cash compensation under deferred compensation plan	100%
Amounts accrued under the deferred compensation plan	$ 10	6.1
Swiss
Defined Benefit Plan Disclosure [Line Items]
Unfunded net pension obligation	4	1.9
Plan assets	$ 18.4	$ 14.1

Supplemental Financial Inform_3

Supplemental Financial Information - Trade Receivables, Net (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	$ (1)	$ (1.4)	$ (6.2)
Additions charged to costs and expenses	(19.7)	(18.9)	(18.4)
Deductions and other	(3.2)	19.3	23.2
Ending balance	(23.9)	(1)	(1.4)
Allowance for Doubtful Accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	(1)	(1.3)	(3.1)
Additions charged to costs and expenses	(2.2)	(0.2)	(0.3)
Deductions and other	0.4	0.5	2.1
Ending balance	(2.8)	(1)	(1.3)
Allowance for Cash Discounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	0	(0.1)	(3.1)
Additions charged to costs and expenses	(17.5)	(18.7)	(18.1)
Deductions and other	(3.6)	18.8	21.1
Ending balance	$ (21.1)	$ 0	$ (0.1)

Supplemental Financial Inform_4

Supplemental Financial Information - Long-Lived Assets (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 314.1	$ 324.9
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	105	109.2
Europe, Middle East, and Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	170.8	176.9
Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	37.2	38.4
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 1.1	$ 0.4

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Nov. 30, 2024	Sep. 30, 2024	Nov. 22, 2024
Time Vested Restricted Stock Units
Subsequent Event [Line Items]
Awards granted (in shares)		1,437,311
Vesting period		3 years
Subsequent Event | Time Vested Restricted Stock Units
Subsequent Event [Line Items]
Awards granted (in shares)	1,400,000
Vesting period	3 years
Subsequent Event | Performance Based Restricted Stock Units
Subsequent Event [Line Items]
Awards granted (in shares)	500,000
Vesting period	3 years
Subsequent Event | Minimum | Employee Severance
Subsequent Event [Line Items]
Restructuring cost			$ 25
Subsequent Event | Minimum | Asset Impairments And Write-offs
Subsequent Event [Line Items]
Restructuring cost			10
Subsequent Event | Maximum | Employee Severance
Subsequent Event [Line Items]
Restructuring cost			30
Subsequent Event | Maximum | Asset Impairments And Write-offs
Subsequent Event [Line Items]
Restructuring cost			$ 15